

EDUCATION:**1960 - 1966**

- University of Edinburgh Medical School Edinburgh, Scotland, United Kingdom

1966 - 1967

- Royal Infirmary, University of Edinburgh, Scotland, United Kingdom
- Medical House Officer (6 months) Wards 26 and 27 (Professor KW Donald)
Surgical Officer (6 months) Wards 7 and 8 (Professor Sir John Bruce)

1967 - 1969

- Wayne State University Medical School Michigan, USA
Medical Resident (Professor Bing)

1969 - 1972

- Mayo Clinic, Rochester, Minnesota, USA
Medical Resident then Clinical and Research Fellow in Hematology and Hematologic Oncology
Masters project in cellular immunology in hematologic malignancies.

LICENSURE

1965	ECFMG (U.S.)
1966	British Medical Association License (Registration: 0223285)
1972	National Board of Medical Examiners (USA, FLEX)
1972	Minnesota State License 0203205
1973	Arizona State License 8048
1993-2008	California State License C043179

NCI INVESTIGATOR NUMBER: 10184**SPECIALTY BOARD CERTIFICATION**

1972	Diplomate American Board of Internal Medicine (ABIM)
1974	Diplomate ABIM Hematology
1975	Diplomate ABIM Oncology

ACADEMIC APPOINTMENTS

- 1972 - 1973 **Instructor**
Section of Hematology and Oncology
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
- 1973 - 1976 **Assistant Professor of Medicine**
Section of Hematology and Oncology
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
- 1976 - 1980 **Associate Professor of Medicine**
Section of Hematology and Oncology
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
- 1981 - 1992 **Professor of Medicine/Hematology/Oncology**
Section of Hematology and Onco0logy
Department of Internal Medicine
University of Arizona College of Medicine
Tucson, Arizona 86724
- 1989 - 1992 **Professor of Clinical and Laboratory Medicine/Hematology**
Department of Hematology
Charing Cross and Westminster Medical School
University of London
Charing Cross Hospital
Fulham Palace Road
LONDON W6 8RF ENGLAND
- 1992 - 1993 **Professor of Hematology/Oncology**
Division of Hematology/Oncology
Cedars Sinai Medical Center
8700 Beverly Boulevard
Los Angeles, CA 90048

CURRENT POSITIONS

1990-Pres. **Chairman of the Board and International Myeloma Working Group (IMWG)**

International Myeloma Foundation
12650 Riverside Drive, Suite 206
North Hollywood, CA 91607
Telephone: (818) 487-7455
Fax: (818) 487-7454
E-Mail: TheIMF@myeloma.org

1993-Pres. **Director of Hematologic Research and Myeloma Programs**

Aptium Oncology, Inc.
Cedars-Sinai Comprehensive Cancer Center
8201 Beverly Boulevard
Los Angeles, CA 90048
Telephone: (323) 966-3572
Fax: (323) 966-3685
Email: bdurie@aptiumoncology.com

2002-Pres. **Co-Chairman Myeloma Committee for SWOG**

Southwest Oncology Group, Operations Office
14980 Omicron Drive
San Antonio, TX 78245-3217
Telephone: (210) 677-8808
Fax: (210) 677-0006
Website: <http://swog.org>

2005-Pres. **Member of the Sutter Western Division Cancer Research Group**

Independent Affiliate of Member Institution UC Davis
Alta Bates Cancer Care Center
2001 Dwight Way
Berkeley, California 94704
Telephone: 510/204-1591
Fax:
Website:

OTHER PRIOR/ONGOING APPOINTMENTS

University of Arizona

Director, Clinical Hematology
Arizona Health Sciences Center
(University of Arizona)
1979 - 1989

Director Fellowship Teaching Program
Clinical Cell Kinetics Service For Cancer Center
1982-86

Consultant
NIH

Review and Referral branch for cooperative group and/or R01/P01 type grants/contracts dealing with multiple myeloma, biologic response modifiers and drug sensitivity testing.
1975 – ongoing

MAJOR FIELDS OF CLINICAL/RESEARCH ACTIVITY

A. Tumor Types

1. **Hematologic malignancies:** Myeloma: acute/chronic leukemia; Hodgkin's/non-Hodgkin's lymphomas
2. **Selected solid tumors:** Breast carcinoma, malignant melanoma, sarcomas, thyroid carcinoma.

B. Research Interests

1. **Investigation of basic biologic mechanisms** including kinetics, genetics, molecular biology and drug sensitivity/resistance.
2. **Apply new approaches to therapy** including new combination chemotherapy regimens, new phase II agents and biologic agents, such as VELCADE[®], Thalidomide and Revlimid[®].
3. **New imaging techniques** in myeloma including whole body MIBI, whole body FDG/PET or CT/PET and whole body screening MRI.
4. **Role of infection in pathogenesis of myeloma** including bacteria and viruses. Particular interest in "stealth viruses" and role of activated ALU type sequences capable of retro integration.
5. **Phase III clinical trials in myeloma** through SWOG mechanism. Currently P.I. for SWOG 0777 (NCT 00644228) comparing Revlimid[®] low dose dexamethasone with VELCADE[®]/ Revlimid[®]/low dose dexamethasone.

PROFESSIONAL ACTIVITIES

TEACHING RESPONSIBILITIES

Local

- 1972 - 1983 Medical student Hematopathology Course: Lecturer covering hematologic malignancies, syndromes, granulocyte production and function. (Different specific topics each year, 1972 to 1983). Approximately 100 students/class.
- 1983 - 1989 Overall coordinator for medical student course in Hematopathology/clinical correlations.
- 1976 - 1980 Hemostasis and Thrombosis Seminars (annual) - Course 396x (Phase II students): 1. Acquired coagulopathies; 2. Coagulation disorders in malignant and inflammatory disease states. Approximately 15 students.
- 1977 - 1989 Immunology Seminars (annual) - Course 396zz (Phase III students): 1. Pathogenesis and approach to immunologic diseases; 2. Immune deficiency states; 3. Abnormal immune responses (multiple myeloma, lymphomas, leukemia, amyloidosis). Approximately 15 students.
- 1979 Clinical Medicine Preceptor: Certificate for Outstanding Preceptor Clinical Teaching, Class of 1979.
- 1979 - 1989 Hematology, peripheral blood and bone marrow morphology review for Hematology/Oncology Fellows, bi-weekly.
- 1983 - 1992 Weekly hematology teaching conference for Hematology/Oncology fellows (Fridays: noon).
- 1992 - Ong. Fellow/house staff teaching Cedars-Sinai/UCLA.
- 1997 - Ong. Preceptor for research fellowship rotations at Cedars-Sinai Medical Center/ UCLA in area of multiple myeloma and related disorders.

Regional

- 1976 - 1980 Leukemia Society of America, Arizona Chapter - Presenter at Annual Symposia, 1976 (Phoenix), 1977 (Tucson), 1978 (Phoenix), 1979 (Tucson), 1980 (Phoenix).

- 1978 Arizona Medical Association - Chairman, Leukemia Teaching Symposia, April.
- 1980 Chairman for regional MKSAP-B course in Hematology.
- 1980 Presenter for regional MKSAP-A course in Oncology.
- 1987 Arizona Medical Association - Chairman, Immunoproliferative Disorders, Teaching Symposia, May 1987.
- 1994 Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Myeloma Update.
- 1997 Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, What Causes Myeloma?
- 1999 Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Plasma RNA in Multiple Myeloma, Clinical Relevance and Molecular Pathology.
- 2001 Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Novel Therapies in Multiple Myeloma.
- 2002 Grand Rounds, Cedars-Sinai Comprehensive Cancer Center, Role of FDG/PET Scanning in Multiple Myeloma.
- 2003 Education Session, Comprehensive Cancer Center of the Desert, Palm Springs, Novel Therapies and New Technologies in Multiple Myeloma.
- 2004 CME Conference, Hematologic Malignancies, Marina del Rey, CA, New Approaches to Diagnosis and Staging for Multiple Myeloma and Related Disorders, February 2004.
- 2005 CME Conference, Hematologic Malignancies, Marina del Rey, CA, New Paradigm for Myeloma Therapy Decisions, January 2005
- 2006 Grand Rounds, Guidelines for Bisphosphonate Use, Miami, FL, March 2006
- CME Conference, Novel Therapies for Myeloma, Philadelphia, PA, August 2006
- CME Conference, Frontline Therapy for Myeloma, Rhode Island, October 2006
- 2007 CME Conference, New Agents for Myeloma, Los Angeles, CA, February 2007
- CME Conference, Role of Transplant for Myeloma, Houston, TX, March 2007
- CME Conference, Use of Freelite to Monitor Myeloma, American Association of Clinical Pathologists, San Diego, CA, July 2007
- 2008 Joint HOPA/ISOPP 2008 Annual Meeting, Anaheim, CA, July 2008

ASH Teaching Sessions

National

American Society of Hematology Teaching Sessions

December 1977	San Diego	Clinical application of cell kinetics
December 1978	New Orleans	Basic concepts in multiple myeloma
December 1979	Phoenix	Current concepts in multiple myeloma
December 1983	San Francisco	Approaches to treatment for multiple myeloma
December 1984	Miami	Organizing chairman ASH myeloma teaching sessions
December 1985	New Orleans	Organizing chairman ASH myeloma teaching sessions
December 1986	San Francisco	Organizing chairman ASH myeloma teaching sessions
December 1988	San Antonio	Organizing chairman ASH myeloma teaching sessions
August 1992	London	Organizing chairman ISH/ASH myeloma teaching sessions
December 1992	Los Angeles	Organizing chairman ASH myeloma teaching sessions
December 1996	Seattle	Chairman, Meet the professor, ASH myeloma teaching sessions
December 1997	San Diego	Chairman: Brainstorming session on myeloma research
December 1999	New Orleans	Co-Chair Super Friday Session, New Advances in Biology and Treatment of myeloma
December 2000	San Francisco	Co-Chair Super Friday Session, New Advances in Multiple Myeloma.
December 2001	Orlando	Co-Chair Super Friday Session, New Advances in Myeloma.
December 2002	Philadelphia	Coordinating/Sponsor Super Friday Session, Challenging Cases in Multiple Myeloma.
December 2003	San Diego	Planning Committee Super Friday Session, Challenging Cases in Multiple Myeloma
December 2004	San Diego	Chairman for Super Friday Session on Multiple Myeloma
December 2005	Atlanta	Chairman for Super Friday Session on Multiple Myeloma
December 2006	Orlando	Chairman for Super Friday Session on Multiple Myeloma
December 2007	Atlanta	Chairman for Super Friday Session on Multiple Myeloma
December 2008	San Francisco	Scheduled chairman for Super Friday Session on Multiple Myeloma

British Society of Haematology

March 1991 Glasgow Organizing chairman BSH teaching sessions

Selected Teaching Sessions (abbreviated)

National

October 1986	Washington	The George Washington University Medical Center. Review course in Hematology: Plasma cell disorders session.
September 1986	Columbus	FACP course in Plasma cell disorders
September 1987	Boston	Harvard (Dana-Farber) Cancer Medicine session on plasma cell disorders, chaired.
October 1988	Washington	The George Washington University Medical Center. Review course in Hematology: Plasma cell disorders session.
October 1990	Washington	The George Washington University Medical Center. Review course in Hematology: Plasma cell disorders session.
October 1992	Washington	The George Washington University Medical Center. Review course in Hematology: Plasma cell disorders session.
February 1994	Keystone	IBMTR/AABMTR Annual Symposium. Role of autologous and allogenic transplantation in multiple myeloma.
February 1995	Keystone	IBMTR/AABMTR Annual Symposium. Twin transplants in multiple myeloma.
August 1996	Cleveland	Cleveland Clinic Seminar. What causes myeloma: review and update.
October 1996	San Diego	Scripps Cancer Symposium. Current approaches to myeloma treatment.
September 1997	Monterey	Inn at Spanish Bay. Alta Bates Symposium. Role of high dose therapy and transplantation in myeloma.

October 1998	San Diego	Scripps Cancer Symposium. Current approaches to multiple myeloma.
January 2003	Los Angeles	Regional Meeting. Frontline Therapy of Myeloma
April 2003	San Diego	SWOG Meeting. Analysis of Frontline Transplant Trial
	Baltimore	CMS Presentation. Role of PET/CT Imaging In Myeloma.
June 2003	Raleigh/Durham	Regional Meeting. What Causes Myeloma?
August 2003	Atlanta	Emery Presentation. Thalidomide/dexamethasone Therapy: Summary Results
October 2003	Seattle	SWOG Meeting. New Imids Review
March 2004	Minneapolis	Role of DNA SNPs Analysis
April 2004	Denver	Annual Myeloma/Lymphoma Meeting: New Approaches to Myeloma Staging
April 2004	Washington, DC	NCI/NIH: End Points Response Criteria
May 2004	Boston	Review Meeting: Role of Molecular Testing In Myeloma
June 2004	New Orleans	ASCO: Frontline VELCADE® Therapy
July 2004	San Jose	Regional Meeting: Presenting Features of Myeloma
October 2004	New York	Lymphoma/Myeloma Meeting: Role of Freelite® Testing in Myeloma
	Kansas City	SWOG Meeting: Molecular Testing in the Cooperative Group Setting
November 2004	San Diego	Regional Meeting: Management of Myeloma Bone Disease
January 2005	Las Vegas	Annual Myeloma/Lymphoma Meeting: Prognostic Factors in Myeloma
February 2005	Dallas	Regional Meeting: Presenting Features of Myeloma

March 2005	Washington DC	FDA/ODAC Meeting: Bisphosphonates and Osteonecrosis of the Jaw
	Atlanta	Regional Meeting: New Clinical Trends in Myeloma
May 2005	New York	Overview Meeting: DNA SNPs in Myeloma
	Orlando	ASCO Meeting: PET Imaging in Myeloma
June 2005	Los Angeles	Regional Meeting: Frontline Therapy for Myeloma
August 2005	Baltimore	Regional Meeting: Risk Factors for Osteonecrosis of the Jaw
October 2005	Dallas	SWOG Meeting: New Frontline Trial Options
February 2006	San Francisco	Regional Meeting: Epidemiology of Myeloma
March 2006	Miami	Myeloma/Lymphoma Workshop: New Approaches to Myeloma Staging
	Ft. Lauderdale	Investigators Meeting: Frontline Therapy for Myeloma
April 2006	Salt Lake City	SWOG Meeting: Phase III Protocols for Myeloma
June 2006	Atlanta	ASCO Meeting: Role of DNA SNPs in Myeloma
July 2006	Portland, OR	Clinical Trials Discussion: Novel Therapies In Myeloma
October 2006	Rhode Island	Hem/Onc Specialists Regional Meeting: Case Discussions: Treatment Options for Myeloma
	New York	Annual Lymphoma/Myeloma Meeting: Anatomic and Functional Staging in Myeloma
December 2006	Orlando	Osteonecrosis of the Jaw Related to Bisphosphonate Use
February 2007	Los Angeles	Bone Disease in Myeloma
March 2007	Houston	Frontline Therapy for Myeloma

April 2007	Phoenix	New Clinical Trials Available in Myeloma
June 2007	Chicago	ASCO Meeting: Revlimid as Frontline Therapy
July 2007	Teaneck, NJ	Presenting Features of Myeloma
August 2007	Santa Monica	Management of Toxicities with Novel Therapies
October 2007	Huntington Beach	SWOG Meeting: New Phase III Trials
December 2007	Atlanta	ASH Meeting: Multiple Presentations
February 2008	New York	Celgene Roadmap Meeting
March 2008	Las Vegas	Nurse Leadership Board Meeting: Management of Novel Therapy Toxicities
April 2008	Phoenix	Role of Novel Therapy in Frontline Therapy
May 2008	Atlanta	SWOG Meeting: Revlimid/dexamethasone vs. VELCADE/Revlimid/dexamethasone 0777 Protocol
	Chicago	ASCO Meeting: Lenalidomide Advisory Board; Plerixafor
June 2008	Anaheim	HOPA Meeting: Current Strategies to Improve Outcomes in Myeloma
August 2008	Los Angeles	Vital Options Radio Show: New Approaches to Myeloma Therapy

International (Selected)

1986	International Society of Hematology - Myeloma symposium: Immunobiology of myeloma, Sydney, Australia, 1986.
1987	Italian Society of Hematology, Myeloma Symposium, Sicily, March 1987.
1987	First International Myeloma Workshop, Blenheim Palace, Oxfordshire, U.K., October 1987. Scientific Advisor, Keynote Speaker
1989	Second International Myeloma Workshop, Houston, Texas, U.S.A., July 1989. Scientific Advisor/Organizing Committee, Invited Speaker

- 1990 European Myeloma Research Group (EMRG) inaugural meeting, London, March 1990. (Chairman)
- 1990 International Cancer Update: Cannes, France, November 1990. (Chairman)
- 1991 Role of biologic therapy in Myeloma: Sydney, Australia, May 1991. (Chairman)
- 1991 Multiple Myeloma From Biology to Therapy, Third International Workshop: Torino, Italy, April 1991. Scientific Advisor, Chairman European Committee
- 1992 Role of erythropoietin in treatment of Myeloma. Symposium, ISH (London), August 1992. Chairman, Organizing Committee
- 1993 Fourth International Workshop: Mayo Clinic, Rochester, Minnesota, 1993. Scientific Advisor, Program Committee: invited speaker
- 1994 Multiple Myeloma, An International Perspective. The Second Clinical Conference of the International Myeloma Foundation: The Regent Singapore, March 1994. Organizing Chairman
- 1994 The demographics of multiple myeloma. Symposium, Royal College of Physicians, London, May 1994.
- 1995 Fifth International Workshop on Multiple Myeloma: La Baule, France, September 1995. Scientific Advisor, Program Committee: invited speaker
- 1996 Mechanisms and treatment of bone disease in myeloma. Symposium, Vienna, Austria, September 1996.
- 1997 Current concepts of myeloma pathogenesis. Symposium, Sydney, Australia, April 1997.
- 1997 Sixth International Workshop on Multiple Myeloma, Harvard Medical School, Dana-Farber Cancer Institute, Boston, Massachusetts, June 1997. .Scientific Advisor, Program Committee: invited speaker
- 1998 What's new for myeloma treatment. Symposium, Toronto, Canada, March 1998.
- 1998 Standard dose chemotherapy for myeloma. Symposium, Royal College of Physicians, London, July 1998.
- 1998 Role of viruses and retroviruses in the pathogenesis of myeloma. Symposium, Geneva, Switzerland, September 1998.
- 1998 New paradigms in the management of myeloma. Symposium, Sao Paulo, Brazil, October 1998.

- 1999 Seventh International Multiple Myeloma Workshop: Stockholm, Sweden, September 1999. Scientific Advisor, Program Committee: invited speaker
- 2001 Eighth International Myeloma Workshop: Banff, Canada, May 2001. Scientific Advisor, Program Committee: invited speaker
- 2003 Ninth International Myeloma Workshop: Salamanca, Spain, May 2003. Scientific Advisor, Program Committee: invited speaker
- 2005 Eleventh International Myeloma Workshop: Sydney, Australia, April 2005. Scientific Advisor, Program Committee: invited speaker
- 2006 Grand Rounds, Staging of Myeloma, Heidelberg, Germany, March 2006
- CME Conference: Management of Myeloma, EHA Meeting, Amsterdam, June 2006
- CME Conference: Bone Disease in Myeloma, Prague, Czech Republic, September 2006
- 2007 Annual Meeting: Bone Disease in Myeloma, Paris, France, April 2007.
- Anniversary Meeting: Overview of Myeloma Management, Tel Aviv, Israel, May 2007.
- Role of Bisphosphonates, Vienna, Austria, EHA Meeting, June 2007.
- Thirteenth International Myeloma Workshop: Response Evaluation in Myeloma, Kos, Greece, June 2007.
- Annual Investigator Meeting: Role of VELCADE® as Frontline Therapy, Sao Paulo, Brazil, August 2007.
- Investigator Meeting: Thalidomide Therapy in Myeloma, Istanbul, Turkey, August 2007.
- Annual Myeloma Meeting: Presenting Features of Myeloma, Naples, Italy, September 2007.
- Investigators Meeting: New Drugs for Myeloma, St. Petersburg, Russia, September 2007.
- Chair, First International Myeloma Symposium, Beijing, China, Multiple Presentations, October 2007.
- Myeloma Grand Rounds, Hong Kong, China, October 2007.

- 2008 Chair, International Workshop/Board Meeting: Role of Imids in Myeloma. Torino, Italy, February 2008.
- IMF Scientific Advisory Board Meeting: New Response Criteria, Bermuda, April 2008.
- EHA Meeting: Durable Remission and Quality of Life in Myeloma Therapy, Copenhagen, Denmark, June 2008.

COMMITTEES

Local

- 1976 Medical Service Plan Committee member, Arizona Health Sciences Center.
- 1976 - 1989 Medical Ethics Review Committee member, Arizona Health Sciences Center.
- 1977 - 1978 Subcommittees for Basic Laboratory Support for Planned Cancer Center member, Arizona Health Sciences Center.
- 1977 - 1979 Committee (campus-wide) for Review of Recombinase DNA Research (Biohazards Committee) member.
- 1977 - 1984 Radioisotope Committee member, Arizona Health Sciences Center.
- 1985 - 1990 Medical Staff Appeals Committee member.
- 1985 – 1990 Executive Committee for the University Medical Center, member.
- 1985 - 1990 Credentials Committee for the University Medical Center, member.
- 1987 - 1988 UMC Bone Marrow Transplantation Committee. Chairman.
- 1989 - 1992 Multiple Committees: University of London (Haematology).
- 1992 Hematology Research Committee: Mayo Clinic.
- 1992 - 2002 Bone Marrow Transplantation/Stem Cell Support Committee, Cedars-Sinai Medical Center, Los Angeles.
- 2002 - 2007 Chair: Myeloma Research Committee Cedars-Sinai Comprehensive Cancer Center, Los Angeles.

Regional

- 1974 - 1990 Member, Leukemia Committee, Southwest Oncology Group (SWOG).
- 1974 - 1990 Member, Myeloma Committee, SWOG
- 1974 - 1990 Member, Ad Hoc Committee for Thyroid Cancer Screening (in patients with prior head and neck irradiation) in Arizona.
- 1979 - 1984 Councilor for Western Section, American Federation for Clinical Research

National and International

- 1976 Member NIH Ad Hoc Working Group of Hodgkin's Disease, Lymphomas and Plasma Cell Neoplasm (Chairman: Daniel E. Bergsagel). Responsible for plasma cell neoplasm's section.
- 1977 Member, NCI Committee to Review Polyamines in Cancer (Chairman: Seymour E. Cohen). Report published in Cancer Research 37:361-365, 1982.
- 1978 Member, Cooperative Group Basic Science Review Committee (set-up by Cooperative Group Chairman's Committee Chairman Dr. Barth Hoogstraten). Basic Research, Masson Publishing, ch. 20, 361-365.
- 1979 - 1982 Member, Membership Committee of SWOG.
- 1981 - 1989 Co-chairman, Myeloma Committee for SWOG.
- 1983 - 1989 Chairman, Membership Committee, American Society of Hematology.
- 1984 - 1992 Editorial Advisory Board, Leukemia Reviews International (Marvin A. Rich, Ed), Volume 2, Marcel Dekker, Inc.
- 1987 - 1992 Editorial Advisory Board, Molecular Biotherapy, the international journal for the application of biologicals in clinical or veterinary practice.
- 1984 - 1992 Member, National Thyroid Cancer Study Group Committee.
- 1987 Member, Scientific Abstract Review Committee for the American Society of Hematology (Dec. 1987 meeting).
- 1990 - Ongoing International Medical Editorial Board. Haematology Digest.
- 1990 - 1993 Chairman EORTC myeloma committee (Paris).
- 1990 - 1993 Co-Chairman MRC myeloma committee (London).

1990 - 1993	Chairman EMRG (European Myeloma Research Group). Inaugural meeting, London 1990; Brussels and Torino 1991.
1990 - 1994	Chairman IMF (International Myeloma Foundation). Board of Scientific Advisoris.
1990 - 1993	Video Journal of Oncology - New Approaches in the Diagnosis and Treatment of Multiple Myeloma. Charing Cross Hospital (University of London), vol. IV, No. 1.
1990 - Ongoing	Founding Executive Board Member. International Myeloma Foundation (IMF) (October 1990).
1990 - Ongoing	Chairman, of the Executive Board, International Myeloma Foundation (IMF) (October 1990).
1991	Chairman European Scientific Advisors for International Myeloma Workshop, Torino, Italy, 1991.
1991 - Ongoing	Regional Editor for "FORUM." Trends in Experimental and clinical medicine edited by the "FORUM" for biomedical training.
1991 - 1992	Chairman, Scientific Advisory Board, Sharon Allen Leukemia Trust.
1991 - Ongoing	Member of Advisory Board of International Journal of Clinical and Laboratory Research.
1990 - Ongoing	Medical Director, International Myeloma Foundation.
2002 - Ongoing	Co-Chairman of Myeloma Committee for Southwest Oncology Group (SWOG)
2004 - Ongoing	Chairman of Scientific Advisor Committee for SNP Genetic Project Bank on a Cure™
2005 - Ongoing	Member of Editorial Advisory Board of Clinical Advances in Hematology and Oncology
2005 - Ongoing	Section Editor for Clinical Lymphoma and Myeloma

Memberships / Societies / Honors

British Medical Association (BMA)
British Society of Haematology (BSH)
British Oncology Society (BOS)
American Medical Association (AMA)
American Society of Hematology (ASH)
American Society of Clinical Oncology (ASCO)
American Society of Cancer Research (AACR)
European Oncology Society (EOS)
Cell Kinetic Society (CKS)
American Federation for Clinical Research (AFCR)
International Society of Experimental Hematology (ISEH)
Society for Interferon Research
Mayo Alumni Association
Scholar Leukemia Society of America
Indian Journal of Hematology and Blood Transfusion, International Editorial Board

THESIS AND DISSERTATION COMMITTEES

- 1978 Pharmacology Ph.D. thesis Reader for **Michael Rosenblum**, "Distribution, Metabolism and Excretion of Polyamines in Rats and Humans," Graduate College, University of Arizona.
- 1979 Human Genetics Ph.D. thesis Director for **Debra Saxe**, "Melanoma: Chromosomal Aberrations and Their Relationship to Drug Resistance," Graduate College, University of Arizona.
- 1981 Pharmacology Ph.D. thesis Reader for **Chuck Prussack**, "Acetyl Polyamines as Markers for Cancer," Graduate College, University of Arizona.
- 2003 Immunology PhD thesis Reader for **Ross Brown**, "Molecular immunology in multiple myeloma," University of NSW, Sydney, Australia.

SPONSOR FOR HEMATOLOGY / ONCOLOGY FELLOWSHIPS

Maria Alma Rodriguez. Investigation of the relationship between herpes virus infections (eg, EBV) and myeloma. Mentor for Clinical Oncology Career Development Award, 1984-1985.

William S. Dalton. The study of multiple drug resistance in multiple myeloma. Mentor for Clinical Oncology Career Development Award, 1984.

Marilyn Croghan. Efficacy of biologic agents (interferon, interleukins, tumor necrosis factors, glucocorticoids, androgens) in drug resistant myeloma. Research fellowship sponsor 1986-1988.

SCHOLARSHIPS AND AWARDS

- 1976 Scholar, Leukemia Society of America - \$100,000; annual for five years.
- 1976 Awarded patent rights for method of high speed scintillation auto-radiography (Patent numbers: US4 4,035,155; Canada 254,488; France 76.32880; Britain 45302/76; Germany P 26 49 902.5-52).
- 1979 Outstanding Preceptor Clinical Teaching
- 1986 Annual Hematology Research Award: Visiting Lectureship, University of Nova Scotia, Canada.
- 1991 The Fifth Annual Hematologic Research Foundation Award (U.S.: New York) Visiting Lectureship.
- 2003 Annual Nuclear Medicine Society Award. 1st Prize Award: Best Clinical Medicine Study 2002. Whole body FDG/PET scanning in multiple myeloma.
- 2004 Honoree: International Myeloma Foundation Achievement Award, Los Angeles, CA, November 2005
- 2006 Honoree: Robert A. Kyle Lifetime Achievement Award at the National Press Club in Washington D.C., May 2006
- 2007 Outstanding Speaker Award, Advances in Clinical Chemistry, Education, and New Technology, July 2008.

RESEARCH GRANTS AND FELLOWSHIPS RECEIVED

- 1971 - 1972 Research Scholarship Mayo Clinic (University of Minnesota). Evaluation of cell mediated immunity (in-vitro) in patients with myelomonocytic leukemia.
- 1972 - 1975 Clinical Investigator Human Tumor Kinetic Center (University of Arizona). NIH Contract NCI-C73-3717. Annual budget of \$130,000.
- 1975 - 1978 Principal Investigator NCI-C-73-3713
Medical Oncology Program Project Grant (CA-17904)
Principal Investigator Section IIA: Cell kinetics of multiple myeloma: Differentiation of cell cycle phases by computerized image analysis.
Annual budget: \$55,629.
- 1975 - 1980 Principal Investigator Section IIC (Principal Investigator - Dr. D H Russell): Polyamines as potential markers of cancer and of the efficacy of therapy.
Annual budget: \$43,373.

- 1975 - 1978 Co-investigator Section IIIC (Principal Investigator - Dr. P Bartels): Computer analysis of human lymphocyte populations. Annual budget: \$83,146.
- 1975 - 1980 Co-investigator Section VA (Principal Investigator - Dr. D Huestis): Transfusion support of patients with cancer by leukopheresis and platelet pheresis. Annual budget: \$97,164.
- 1976 - 1981 Research Scholar Leukemia Society of America: \$100,000 for five years. Application of rapid autoradiography and polyamine determinations in clinical haematology/oncology.
- 1978 - 1982 Sister chromatid exchange and nucleolar organizer regions in peripheral blood and bone marrow cells of patients with breast carcinoma before and after adjuvant chemotherapy. Annual budget: \$39,000.
- 1979 - 1980 Principal Investigator: Use of Clodronate disodium in the treatment of hypercalcemia in patients with malignant disease. Proctor & Gamble Co., \$64,000.
- 1979 - 1982 Principal Investigator: Poly (ICLC) as interferon inducer in patients with refractory multiple myeloma (in collaboration with Arthur Levine MD, NCI).
- 1979 - 1984 In-vitro stem cell (blast) assay in acute myelogenous leukemia: modification and application for cytogenetic analysis and drug sensitivity testing. Funding: Upjohn Co., Kalamazoo, Michigan and Regional VFW grant. Total: \$15,000.
- 1979 - 1984 Phase III evaluation of VCP \pm levamisole versus VMCP-VBAP \pm levamisole in previously untreated multiple myeloma. Southwest Oncology Group Study - 7927/28. Principal investigator (440 patients in study).
- 1980 - 1989 Multiple myeloma: kinetics, tumor markers, clonogenic assay studies. Principal investigator POI section III C MOPP Grant CA 17904. Total budget: \$557,462 over 5 years.
- 1980 - 1982 Phase II evaluation of bisantrene in refractory multiple myeloma. Southwest Oncology Group Study - 8018. Principal investigator.
- 1981 - 1983 Catrx studies: the efficacy of cartilage extracts against tumor cells - Lescarden, Ltd. \$85,000.
- 1983 - 1986 The effects of 1-25 dihydroxyvitamin D₃ (and related analogs) on myeloma cell proliferation and differentiation. Hoffman-LaRouche Inc. Principal Investigator.
- 1983 - 1986 Danazol: Efficacy in treatment of mild-moderate hemophilia and immune thrombocytopenic states. Principal Investigator. Winthrop Labs, New York (Free drug supplied for studies).

- 1984 - 1987 Evaluation of red cell polyamine levels as markers of response to chemotherapy. Part of polyamine project. (Dr. DH Russell, Principal Investigator).
- 1984 - 1986 Phase II evaluation of 13-cis retinoic acid in refractory multiple myeloma. Part of Retinoid program project (Dr. F Meyskens). Principal Investigator.
- 1984 - 1989 Phase II evaluation of high dose cytosine arabinoside in refractory multiple myeloma. Principal Investigator (MOPP grant).
- 1984 - 1986 In-vitro evaluation of suppression of BFU-E by myeloma cells. Co-investigators: W Walton/B Durie.
- 1985 - 1989 SWOG Phase III study of high dose Arac alone versus \pm m-AMSA or mitoxantrone for refractory acute myeloid leukemia or CML in blast crisis. Principal Investigator (NCI-sponsored). Accrual 150 patients.
- 1986 - 1989 Trial of long-acting somatostatin analogue SMS 201-995 for malignant carcinoid. R Rifkin / B Durie (Sandoz sponsored).
- 1986 - 1988 Phase II study of dexamethasone + α_2 interferon in hematologic malignancies. Principal Investigator. Schering Corporation sponsored study (\$15,000).
- 1986 - 1989 Phase II evaluation of VAD + verapamil as treatment for refractory multiple myeloma. B Dalton / B Durie Co-Principal Investigators.
- 1987 - 1989 SWOG Phase II study for primarily untreated myeloma-VMCP-VBAP/VAD/VMCPP-VBAPP; α_2 interferon maintenance. Principal Investigator. NCI-sponsored. Accrual 500 patients.
- 1987 - 1989 Investigation of 3 new B-cell mitogens in-vitro (ORF: 21757-000; 21765-097; 22444-000). Sponsored by Ortho Pharmaceutical Company. Principal Investigator.
- 1987 - 1989 Phase I-II study of recombinant GM-CSF in neutropenic states. Immunex sponsored study. Hersch/Durie/Salmon.
- 1990 - 1993 Phase III study ABCMP \pm alpha interferon MRC study UK (primary induction therapy). Co-investigator with Prof. MacLennan, Birmingham.
- 1991 - 1993 Phase II study VAD \pm Cyclosporin for refractory myeloma. Principal Investigator. EORTC study, Paris.
- 1994 - 1996 Phase II study VAD + PSC 833 for refractory myeloma. Principal Investigator. Cedars-Sinai Comprehensive Cancer Center, Los Angeles.
- 1998 - 2001 Phase II study of Zoledronate for hypercalcemia. Investigator. Cedars-Sinai Comprehensive Cancer Center, Los Angeles.

- 1998 - 2002 Phase II study of Zoledronate for the treatment of bone disease in myeloma. Investigator. Cedars-Sinai Comprehensive Cancer Center, Los Angeles.
- 2003 - 2004 Phase II study of PS-341 (Velcade) Alone and in Combination With Dexamethasone In Previously Untreated Multiple Myeloma Patients. Jagannath/Durie/Wolf. Salick Health Care sponsored study. Grant Support from Millennium Pharmaceutical Co (\$300,000 for treatment protocol, \$50,400 for molecular studies).
- 2003 - 2005 An Open-Label Pilot Study to Evaluate the Effects of Alternate Dosing of Procrit® (Epoetin Alfa) In the Treatment of Anemic Cancer Patients Receiving Chemotherapy. Protocol No. PR02-27-028. Principal Investigator for Salick Health Care. Grant support from Ortho Biotech (\$120,000).
- 2004 - 2006 Phase III evaluation of Thalidomide/Dexamethasone With and Without Bortezomib (VELCADE®) in Frontline Myeloma. (S0522) A Southwest Oncology Group (SWOG) study supported by Millennium Pharmaceuticals. **Principal Investigators:** Brian G.M. Durie/Bart Barlogie. (Not Activated)
- 2005 – 2008 Phase II evaluation of Bortezomib (Velcade), Cytosan, Dexamethasone, and Thalidomide in Frontline myeloma. A Millenium Pharmaceuticals supported study. (\$600,000)
Principal Investigator: Brian G.M. Durie
- 2009 Phase III evaluation of Revlimid®/Dexamethasone With and Without Bortezomib (VELCADE®) in Frontline Myeloma. (S0777) A Southwest Oncology Group (SWOG) study supported by Millennium Pharmaceuticals. **Principal Investigators:** Brian G.M. Durie/Bart Barlogie.

SCIENTIFIC LECTURES AND PRESENTATIONS

1. Durie BGM, Taswell HF: HLA antigens in myelomonocytic leukemia: Results in 50 patients. Presented at International Congress of Transfusion, Washington, DC, August, 1972.
2. Durie BGM, Salmon SE: A new simple staging system for multiple myeloma. Presented at the Sixty-Fourth Annual Meeting of the Proceedings of the American Association for Cancer Research, Atlantic City, NJ, April 11-13, 1973.
3. Sieber OF, Durie BGM, Hattler BG, Salmon SE, Fulginiti VA: Spontaneous evolution of immune competence of Di-George syndrome. Accepted for presentation at Immunology Session, American Pediatric Society, May 2, 1974, Washington, DC.
4. Durie BGM, Salmon SE: High-speed scintillation (HSARG) for clinical and research hematology. Abstract 20, p54. Presented at the Seventeenth Annual Meeting of the American Society of Hematology, Atlanta, Georgia, December 7-10, 1974.
5. Russell DH, Durie BGM, Salmon SE: Spermidine in the serum and urine of cancer patients during chemotherapy as a biochemical marker of clinical response. (Abstract) American Association for Cancer Research, Inc. Presented by Dr. Durie at the Annual Meeting of the American Association for Cancer Research, Inc., San Diego, CA, May 8-10, 1975.
6. Durie BGM, Russell DH, Salmon SE: Polyamines as predictors of success and failure in the chemotherapy of hematologic malignancies. Gordon Research Conference, New Hampshire, June 25, 1975.
7. Durie BGM: Lymphoreticular disease: Review of basic concepts and clinical evaluation. American Society of Clinical Pathology Seminar, St. Louis, MO, July 25, 1977.
8. Durie BGM: Immunodeficiency diseases: Clinical Workshop. American Society of Clinical Pathology National Meeting, Chicago, IL, (1) September 21, 1975.
9. Salmon SE, Durie BGM, Alexanian R: Combination chemotherapy for multiple myeloma. American Society of Hematology 18th Annual Meeting, Dallas, TX, 85:115, December 1975.
10. Durie BGM, Vaught L, Russell DH, Salmon SE: Relationship of cytokinetics to tumor burden and response to treatment in multiple myeloma. Cell Kinetic Society, 1st Annual Meeting, Birmingham, AL, March 1977.
11. Durie BGM: Clinical application of cellular kinetics in hematologic malignancies. Leukemia Society of America Symposium, Birmingham, AL, October 2, 1977.

12. Durie BGM, Mundy GR, Salmon SE: Multiple myeloma, Clinical staging and role of osteoclast-activity factor in localized bone loss. The First Scientific Evaluation Workshop on Localized Bone Loss, Washington, DC, November 5, 1977.
13. Salmon SE, Hamburger AW, Durie BGM: Growth, kinetics and drug sensitivity of human myeloma stem cells. Presented at the Leukemia Society of America, Inc. 4th Annual Memorial Symposium on Etiology and Treatment of Lymphoproliferative Disorders, Boston, MA, April 11, 1978.
14. Salmon SE, Durie BGM, Hamburger AW: A new basis for treatment of multiple myeloma. Presented to the Swiss Society of Hematology, Lausanne, Switzerland, May 25, 1978.
15. Durie BGM: Plasma cell kinetics. Yale Comprehensive Cancer Center Symposium. New Haven, CN, October 25, 1978
16. Durie BGM: Multiple myeloma and paraneoplastic syndromes. Eighth Annual William Dameshek Symposium, Kansas, 1978.
17. Durie BGM, Salmon SE: The plateau phase in multiple myeloma: A reappraisal. Blood 52(5; suppl 1):257. 21st Annual Meeting of the American Society of Hematology, December 2-5, 1978.
18. Durie BGM: Polyamines as biochemical markers of normal and malignant growth. Department of Medical Oncology, St. Bartholomew's Hospital, London, England, July 12, 1978.
19. Durie BGM: Recent developments in multiple myeloma. Royal Marsden Hospital, Sutton, England, July 12, 1978.
20. Durie BGM: Kinetics of soft agar stem cell colonies. Cloning Conference, University of Arizona Cancer Center, Tucson, Arizona, January 4, 1979.
21. Durie BGM, Hellman D, Woolfenden J, Kartchner M, O'Mara R, Salmon SE: Multimodality treatment for high risk thyroid carcinoma. The Second International Conference on the Adjuvant Therapy of Cancer, March 1979.
22. Salmon SE, Buick RN, Soehnen BA, Trent JM, Durie BGM, Alberts DS, Meyskens FL: Human tumor cloning in vitro: insights on biology kinetics and prediction of response to treatment. The Second Annual Conference on Human Tumor Cloning, Tucson, Arizona, January 3-5, 1980.
23. Durie BGM, Brooks RJ: In vitro drug sensitivity testing of leukemic clonogenic cells: Clinical correlations. Third Conference on Human Tumor Cloning, January 20-22, 1982.
24. Salmon SE, Durie BGM: In vitro phase II trial of 4'deoxydoxorubicin (4'deoxyDX) with comparisons to doxorubicin (DX). American Society of Clinical Oncology (ASCO) Annual Meeting, April 1982.

25. Bataille R, Durie BGM, Moon T, Grenier J, Sany: Interet de la Beta-2-microglobulin serique au cours du myeloma multiple etude prospective de 160 malades. Colloque National Sur Les Applications Cliniques de la Beta-2-Microglobuline, Nice, September 1982.
26. Durie BGM: Experimental approaches to drug testing and clonogenic growth of multiple myeloma and acute myelogenous leukemia. International Conference: Predictive Frug Testing on Human Tumor Cells, University Hospital of Zurich, Switzerland, July 1983.
27. Durie BGM: Trends and results in adult acute leukemia. Pathology Seminar Series, March 18, 1983.
28. Durie BGM, McFadden M: In vitro testing of a-2-interferon multiple myeloma: Single agent and combination approaches. Seminar Schering Corp., Meadowlands, New York, April 7, 1983.
29. Durie BGM: Current status of HLA typing on bone marrow transplantation. Am Symp Ariz Soc Med Tech, Tucson, Arizona, May 5, 1983.
30. Durie BGM: Bone marrow transplantation of acute leukemia. Leukemia Society of American Symposium, Arizona, May 6, 1983.
31. Durie BGM: Cytogenetics and the leukemia stem cell assay. Annual Symposium National Society Cytogenetic Techniques, June 6, 1983.
32. Durie BGM: Multiple myeloma: Current approaches to management. Hematology Symposium Series, June 16, 1983.
33. Durie BGM: New experimental approaches in multiple myeloma. University of Montpellier, France, July 25, 1983.
34. Durie BGM: Update on adult acute leukemias. Good Samaritan Hospital, Phoenix, Arizona, August 10, 1983.
35. Durie BGM: Treatment for refractory multiple myeloma. 13th International Chemotherapy Congress, Vienna, Austria, August 31, 1983.
36. Durie BGM: Drug testing with the leukemia stem cell assay: Update of results. 13th International Chemotherapy Congress, Vienna, Austria. September 1, 1983.
37. Durie BGM: The pathogenesis of AIDS syndrome. Deans Rounds, Tucson, Arizona. October 20, 1983.
38. Durie BGM: The principles of haematopoiesis. Biology Seminar Series. October 21, 1983.
39. Durie BGM: New concepts in multiple myeloma. First International Myeloma Symposium, Palermo, Italy. November 10, 1983.

40. Durie BGM: New approaches to myeloma colony growth. International Italian Conference Cell Kinetics and Drug Testing in Oncology (Director: Professor Silverstrini), Genoa, Italy. November 11, 1983.
41. Durie BGM: Diagnosis and treatment of hyperviscosity syndromes. VA Hospital, Tucson, Arizona. November 17, 1983.
42. Durie BGM, Christiansen JA: Improved human myeloma colony growth. Blood 62:189a, 1983. American Society of Hematology, San Francisco, CA. December 5, 1983.
43. Dalton W, Gleason M, CcCloskey T, Durie BGM, Alerts D: Reversal of drug resistance in human multiple myeloma with verapamil (VER): design of a clinical study based on in vitro testing using a drug resistant myeloma cell line. American Society of Clinical Oncology (ASCO). Presented at annual meeting. May 1987.
44. Villar HV, Ranne RD, Dunnington GL, Jones SE, Durie BGM, Grogan TM, Wangenstein SL: The role of splenectomy in the management of hematologic diseases. 36th Annual Southwestern Surgical Congress Meeting, Honolulu, Hawaii. April 21-28, 1984.
45. Durie BGM: Current approaches to the treatment of adult leukemia. Third Winter Symposium on Hematologic Malignancies, Snowbird, Utah. February 18-25, 1984.
46. Durie BGM: Supportive care in acute leukemia. Third Winter Symposium on Hematologic Malignancies, Snowbird, Utah. February 18-25, 1984.
47. Durie BGM, Pond GD, Grogan TM: Current concepts in the diagnosis and treatment of multiple myeloma. Third Winter Symposium on Hematologic Malignancies, Snowbird, Utah. February 18-25, 1984.
48. Durie BGM: Southwest Oncology Group induction protocols for multiple myeloma. Proceedings Myeloma Symposium, Padua, Italy. April 1984.
49. Durie BGM: Multiple myeloma: Current trends and problems in staging and response evaluation. Proceedings Myeloma Symposium, Padua, Italy. April 1984.
50. Durie BGM: Multiple myeloma: Monoclonality versus heterogeneity. University of Cambridge, England. July 17, 1974.
51. Durie BGM: Current approaches to treatment in multiple myeloma. Ludwig Institute, Cambridge, England. July 18, 1984.
52. Durie BGM: Myeloma - Recent advances and future trends. University of Galway, Ireland. September 20, 1984

53. Durie BGM: Current uses of interferon, lymphokines and other biologic response modifiers as anti-cancer therapy. Alta Bates Frontiers in Oncology, Berkeley, California. April 20, 1985.
54. Durie BGM: Clonogenic assays: Can they be used to predict if anti-cancer agents will work? Alta Bates Frontiers in Oncology, Berkeley, California. April 20, 1985.
55. Durie BGM: Poly ICLC in multiple myeloma. Biological Response Modifiers Program, National Cancer Institute, Bethesda, Maryland. April 4, 1985.
56. Durie BGM: The malignant cell in multiple myeloma and Waldenstrom's macroglobulinemia. Proc Eurage Symposium, Monoclonal Gammopathies: Clinical Significance and basic mechanisms (Brussels, Belgium). September 19, 1985.
57. Durie BGM: Update of therapeutic strategies in multiple myeloma. Symposium: New Developments in B cell malignancies, Brussels, Belgium. September 21, 1985.
58. Durie BGM: Biology of multiple myeloma. University of Toronto, Toronto, Canada. January 27, 1986.
59. Durie BGM: Use of alpha-interferons in combinations. Yale University, New Haven, Connecticut. April 8, 1986.
60. Durie BGM, Clouse L, Braich T, Grimm M, Robertone AB: Alpha-2b-interferon/cyclophosphamide combination studies: In vitro and phase I clinical results. Seabrook Island Symposium. April 11, 1986.
61. Durie BGM: Immunobiology of multiple myeloma. Proc Int Soc Hematol, Sydney, Australia. May 15, 1986.
62. Durie BGM: In vitro evaluation of the efficacy of alpha-2b-interferon. Memorial Sloan Kettering, New York, NY. June 11, 1986.
63. Durie BGM: The Immunology of Multiple Myeloma: XXI Congress of the International Society of Hematology: XIX Congress of the International Society of Blood Transfusion. 1986.
64. Durie BGM: Modulation of myeloma growth by lymphokines and accessory cells. 2nd Sicilian International Conference on Hemato-Oncology and Hemato-Immunology. 1986.
65. Dalton W, Gleason M, McCloskey T, Durie BGM, Alberts D: Reversal of drug resistance in human multiple myeloma with verapamil (VER): design of a clinical study based on in vitro testing using a drug resistant myeloma cell line. American Society of Clinical Oncology (ASCO). Presented at annual meeting. May, 1987.

66. Croghan M, Durie BGM, Vela E, Dalton W: Paradoxical increased sensitivity of chemotherapy resistant cells to the biologic agents TNF-alpha, TNF-alpha, IFN- γ , plus corticosteroids. American Association of Cancer Research (Abstract) presented at annual meeting. May, 1987.
67. Rossi JF, Marion SL, Pike JW, Durie BGM, Bataille B, Haussler MR, Janbon CH: 1-25 Dihydroxyvitamin D₃-receptor mediated differentiation of the human myeloma cell line RPMI 8226: phenotypic and functional analysis Workshop on cells and cytokines in bone and cartilage, Davos, Switzerland. December 1986.
68. Durie BGM: Current approaches to multiple myeloma. Roswell Park Memorial Park symposium. July 1986.
69. Durie BGM: Myeloma: biology and therapy. University of Nova Scotia (Halifax). September 25, 1986.
70. Durie BGM: Art, science and medicine (Friday of four seminars). University of Nova Scotia (Halifax). September 25, 1986.
71. Durie BGM: The nature of bone disease in multiple myeloma. University of Washington symposium, Seattle, Washington. October 24, 1986.
72. Durie BGM: Role of biologic response modifiers in hematologic malignancies. University of Tennessee, Memphis, Tennessee. January 15, 1987.
73. Durie BGM: Role of 2^b interferon alone and in combination therapy. Boston symposium. March 31, 1987.
74. Durie BGM: Biology and therapy of multiple myeloma. Duke University Symposium, Seattle meeting. April 7, 1987.
75. Durie BGM: Review of potential role of bone marrow transplantation in multiple myeloma, Seattle Symposium: Fred Hutchison Cancer Center. April 27, 1987.
76. Durie BGM: Current concepts of multiple myeloma. University of Ontario, Hamilton Meeting. May 14, 1987.
77. Durie BGM: Role of 2^b interferon and other biologic agents in multiple myeloma. Argentine Society of Oncology Symposium (1st International), Buenos Aires, Argentina. June 26, 1987.
78. Durie BGM: Plasma cell neoplasms: current status. FACP Symposium, Columbus, Ohio. September 15, 1987.
79. Durie BGM: Plasma cell neoplasms: a review. Harvard Cancer Medicine Course, Boston, Massachusetts. September 16, 1987.
80. Durie BGM: Role of biologic agents in multiple myeloma. Atlantis Symposium.

81. West Palm Beach, Florida. September 18, 1987.
82. Durie BGM: The biology of myeloma. Blenheim Palace Symp. October 24, 1987.
83. Hicks MJ, Durie BGM: Prospective evaluation of immune parameters in patients with multiple myeloma: low circulating T helper cell levels predict poor prognosis. Platform presentation, AACR Symposium, Washington, DC. February, 1988.
84. Karanes C, Kopecky KJ, Durie BGM, Grever M.R.: Increased risk of early death (ed) with high dose ARA-C (HDAC) and m-AMSA compared to HDAC alone or HDAC and Mitoxantrone (Mitox) in high risk nolympocytic leukemia (ANL). American Society of Clinical Oncology (ASCO). Presented at annual meeting. San Francisco, California. March, 1989.
85. Durie BGM: Chemotherapy of myeloma: SWOG studies. Blenheim Palace Symp. October 26, 1987.
86. Durie BGM: New biologic observations and the pathogenesis of multiple myeloma. International Workshop on Multiple Myeloma. Torino, Spain. April 9-12, 1991.
87. Durie BGM: Prognostic factors and staging in myeloma. Second International Myeloma Workshop. Houston, Texas. July 1989.
88. Durie BGM: Risk factors for myeloma: influence of familial genetics and environmental exposures. Fourth International Myeloma Workshop. Mayo Clinic, Rochester. September 1993.
89. Durie BGM: Beta-2 Microglobulin as a Prognostic Factor in Multiple Myeloma. Proceedings of Multiple Myeloma, from Biology to Therapy. Current Concepts. Mulhouse, France. October 24-26, 1994.
90. Durie BGM: The significance of Bcl-2 and L1% in myeloma prognosis. Fifth International Myeloma Workshop. La Baule, France. September 1995.
91. Durie BGM, Gale RP, Klein JP, Pelz C, Nugent ML, Horowitz MM: Allogeneic Bone Marrow Transplantation In Multiple Myeloma: An IBMTR Analysis. Proceedings of the International Workshop on Multiple Myeloma. La Baule, France. September 10-13, 1995.
92. Durie BGM, Gale RP, Klein JP, Pelz C, Nugent ML, Horowitz MM: Allogeneic Bone Marrow Transplantation In Multiple Myeloma: An IBMTR Analysis. American Society of Clinical Oncology (ASCO). March, 1995.
93. Durie BGM, Gale RP, Dubois R, Naumov IM, Anderson KC, Audeh WM, Bergsagel D, Jagannath S, Kyle RA, Oken MM, Perlman M, Rifkin RM, Stone MJ: Multiple Myeloma: Rand-Delphi Analysis of Appropriateness of Peripheral Blood and Bone Marrow Autotransplants with Comparisons Using the Analytic Hierarchy Decision Process. BLOOD. 86:10 Suppl. 1, November 15, 1995.

94. Durie BGM, Gale RP, Dubois R, Naumov IM, Anderson KC, Audeh WM, Bergsagel D, Jagannath S, Kyle RA, Oken MM, Perlman M, Rifkin RM, Stone MJ: Multiple Myeloma: Rand-Delphi Analysis of Appropriateness of Peripheral Blood and Bone Marrow Autotransplants with Comparisons Using the Analytic Hierarchy Decision Process. American Society of Clinical Oncology. March 1996.
95. Durie BGM, Nguyen K, Mochelson M, Waxman A: Technetium - 99m-MIBI Scanning in Multiple Myeloma. BLOOD 88:10, Suppl. 1, page 393a. November 15, 1996.
96. Ludwig H, Fritz E, Neuda J, Durie BGM: Which risk/benefit tradeoffs would lead patients with myeloma to opt for interferon treatment? American Society of Clinical Oncology. May 19, 1997.
97. Durie BGM: Clinical utility of ⁹⁹Tc MiBi imaging in myeloma. Sixth International Myeloma Workshop. Boston, Mass. October 1997.
98. Durie BGM, Villarete L, Farvard A, Ornopia M, Umovitz HB: Circulating nucleotide sequence in myeloma reveals presence of critical 14q32 break point region containing SV40 T-Ag, plus Rb and P₅₃. Proceedings of the American Society of Hematology annual meeting. BLOOD. 90:10 Suppl 1. November 15, 1997.
99. Durie BGM, Villarete L, Farvard A, Ornopia M, Urnovitz HB: Clarithromycin (Biaxin) as primary treatment for myeloma. Proceedings of the American Society of Hematology annual meeting. BLOOD. 90:10 Suppl 1. November 15, 1997.
100. Durie BGM: Expression of Du Alu RNA in the plasma of patients with active myeloma. Seventh International Myeloma Workshop. Stockholm, Sweden. September 1999.
101. Durie BGM: Efficacy of low dose thalidomide in relapsing myeloma. Seventh International Myeloma Workshop. Stockholm, Sweden. September 1999.
102. Durie BGM, Martin J: Stealth Virus and active myeloma: clinical correlations. BLOOD. 94:10 Suppl 1. November 15, 1999.
103. Jacobson J, Hussein M, Barlogie B, Durie BGM, Crowley J: Beta 2 Microglobulin (B2M) and Albumin Define a New Staging System for Multiple Myeloma: The Southwest Oncology Group (SWOG) Experience. BLOOD. 98:11. November 16, 2001 Part 1.
104. Durie BGM, Stepan D: Low Dose Thalidomide Alone and in Combination: Long Term Follow-Up. BLOOD. 98:11. November 16, 2001 Part 1.
105. Durie BGM, Waxman A, D'Agnolo A: Prognostic Value of Whole Body FDG/PET Scanning In Multiple Myeloma. BLOOD. 96:11. November 16, 2002 Part 1.
106. Durie BGM, Jacobson J, Barlogie B, Crowley J: Time to First Progression Is the Best Predictor of Survival Duration in SWOG Standard Dose Chemotherapy Studies. American Society of Hematology (ASH). December 2002.

107. Durie BGM, et al. Circulating Nucleic Acids in multiple myeloma: presence of non-coding/ intergenic DNA reflects disease activity. Abstract #5095. Blood, 106 (11), December 2005. (ASH)
108. Durie BGM, et al. Deep vein thrombosis in myeloma: estimates of problem and recommendations for therapy based upon a survey of members of the International Myeloma Working Group. Abstract #3571. Blood, 108(11), December 2006. (ASH)
109. Durie BGM, Van Ness B, Ramos C, et al. Genetic polymorphisms identify the likelihood of bone disease in myeloma: Correlations with myeloma cell DKK1 expression and high risk gene signatures. Abstract # 816. Blood. 110(11), November 2007 (ASH).
110. Durie B. Treatment of haematological malignancies: Durable remissions and quality of life as primary goals. June 2008 (EHA).

PUBLICATION OF KEY ARTICLES IN MAJOR JOURNALS

<u>Journal</u>	<u>Number</u>
Blood	20
Journal of Clinical Oncology	13
British Journal of Haematology	13
Cancer	10
Cancer Research	8
Lancet	7
Leukemia	7
New England Journal of Medicine	6
Science	4
Journal of the American Medical Association	3
Nature	2

RESEARCH PUBLICATIONS OVERVIEW

Key publications selected from following Research Publications list.

1. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment and survival. Cancer, 36: 842-854, 1975.
2. Durie BGM, Salmon SE: High-speed scintillation autoradiography. Science 190:1093-1095, 1975.
3. Jones Se, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer, 36:90-97, 1975.
4. Alberts DS, Durie BGM, Salmon SE: Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse. Lancet 1:926-928, 1976.
5. Durie BGM, Salmon SE, Russell DH: Polyamines as makers of response and disease activity in cancer chemotherapy. Cancer Res 37:214-221,1977.
6. Durie BGM, Giles HR: Successful treatment of acute leukemia during pregnancy. Arch Int Med 137:90-91, 1977.
7. Alberts DS, Durie BGM, Salmon SE: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep 61:381-388, 1977.
8. Durie BGM, Mundy GR, Salmon SE: Osteoclast stimulating factor. Correlation with measured myeloma cell mass and clinical features in patients with multiple myeloma. Calcified Tissues Res Suppl: 319, 1978.
9. Salmon SE, Hamburger AW, Soehnien BS, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321-1327, 1978.
10. Durie BGM, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma. Blood 55:364-372, 1980.
11. Durie BGM, Russell DH, Salmon SE: The plateau phase in multiple myeloma: A reappraisal Lancet 65-68, July, 1980.
12. Durie BGM, Salmon SE, Mundy GR: Relation of osteoclast activating factor (OAF) production to the extent of bone disease in multiple myeloma. Br J Haematol 47:21-30, 1981.
13. Durie BGM, Hellman D, O'Mara RE, Woolfenden J, Kartchnet M, Salmon Se: High-risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer Clin Trials 4:67-73, 1981.

14. Durie BGM, Cole PW, Chen H-SG, Himmelstein KJ, Salmon SE: Synthesis and metabolism of Bence-Jones protein and calculation of tumor burden in patients with Bence-Jones myeloma. Br J Haematol 47:7-19, 1981.
15. Durie BGM, Salmon SE: The current status and future prospects of treatment for multiple myeloma. In: Clinic in Haematology 11:181-210, 1982.
16. Durie BGM, Persky B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloid production in human myeloma stem cell culture with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 307:1689-1692, 1982.
17. Durie BGM, Young LA, Simon SE: Human myeloma in vitro colony growth: Interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Blood 61:929-934, 1983.
18. Durie BGM: Is myeloma really a monoclonal disease? Br J Haematol 57 (3):357-363, 1984.
19. Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini A, Volta C, Trinalto M, Testa MG, Amadori S, Mandelli F, Durie BGM: Low plasma cell ³(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS) smoldering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br J Haematol 58:689-696, 1984.
20. Durie BGM, Vela E, Baum V, Leibovitz A, Payne CM, Richter LC, Grogan TM, Trent JM: Establishment of two new myeloma cell lines from bilateral pleural effusions: Evidence for sequential in vivo clonal change. Blood 66:548-555, 1985.
21. Durie BGM, Grogan TM: CALLA-positive myeloma: An aggressive subtype with poor survival. Blood 66:229-232, 1985.
22. Bataille R, Durie BGM, Grenier J, Sany J: Prognostic factors and staging in multiple myeloma: A reappraisal. J Clin Oncol, 4:80-87, 1986.
23. Durie BGM, Dixon B, Carter S, Stephens R, Bonnet J, Morrison F, Costanzi J, Salmon SE: Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol, 4:1127-1237, 1986.
24. Garrett I, Durie BGM, Nedwin G, Gillespie A, Bringman T, Sabatini M, Bertolini D, Mundy G: Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. New Engl J Med, 317:526-532, 1987.
25. Durie BGM, Dalton WS: Reversal of drug-resistance in multiple myeloma with verapamil. Brit J Haemat, 68:203-206, 1988.
26. Buzaid A, Durie BGM: Management of refractory myeloma. J Clin Onc. 6(5): (889-905), 1988 .

27. Durie BGM, Grogan TM, Spier C, Vela E, Baum V, Rodriguez MA, Frutiger Y: Myelomonocytic myeloma cell line (LB84-1). Blood, Vol 73, No 3, Feb 15 1989 (p770-776).
28. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman C: Prognostic value of pretreatment serum β_2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood, 75:823-830, 1990.
29. Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan T: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1;Leu-19). Blood, 76:377-382, 1990.
30. Durie BGM: Reversal of Drug Resistance with Verapamil in Multiple myeloma. Brit J Haematol, 76:155-156, September 1990.
31. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE: Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Brit J Haematol, 83:63-67, 1993.
32. Durie B, Urnovitz J. Cell and molecular biology of simian virus 40: Implications for human infections and disease. J Nat Ca Instut. 91(13):1166-1167, 1999.
33. Durie BGM, Urnovitz HB, Murphy WH: RT-PCR amplicons (RNA) in the plasma of multiple myeloma patients, clinical relevance and molecular pathology. Acta Oncologica. 39 (No. 7): 789-796, 2000.
34. Durie BGM, Stepan DE: Efficacy of low dose thalidomide in multiple myeloma. Elec J Onc, 2000, 1, 1-8. Available at www.Elecjoncol.org/ejo/cgi-bin/Escripts2000.pl
35. Durie BGM: Low-dose thalidomide in myeloma: efficacy and biologic significance. Seminars in Oncology, 29 (No 6, Suppl 17): 34-38, 2002.
36. Greipp PR, San Miguel JF, Durie BGM: Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group. The Hem J, Vol 4, Suppl 1: 71, 2003.
37. Durie BGM, Waxman AD, D'Agnolo A, et al. 99m Tc-MIBI and 18F-FDG PET imaging in multiple myeloma. J Nucl Med, 44: 632-634, 2003.
38. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 121: 749-757, 2003.
39. Durie BGM, Waxman AD, D'Agnolo A, et al. 99m Tc-MIBI and 18F-FDG PET imaging in multiple myeloma. J Nucl Med, 44: 632-634, 2003.

40. Durie BGM, Jacobson J, Barlogie B, et al. Time to progression, but not magnitude of regression predicts survival benefit in SWOG standard dose chemotherapy studies for multiple myeloma. J. Clin Onc, 22: 1857-1963, 2004.
41. Durie BGM. New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals. Clin Lymphoma Myeloma, 6 (3): 181-90, 2005.
42. Durie BGM, Katz M, McCoy J, et al: Osteonecrosis of the jaw and bisphosphonates. New Eng. J. Med, Jul 7, 353(1): 99-102, 2005.
43. Durie BGM, Harousseau JL, et al. International uniform response criteria for multiple myeloma. Leukemia, 20:1467-1473, 2006.
44. Durie BG, Attal M, Beksac M, et al. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Pro, 82:516-522, 2007.
45. Durie BGM. (Editorial) Treatment of myeloma- Are we making progress?. New Engl J Med, In Press, August 2008.
46. Durie BGM. (Commentary) Crossover confusion: MPT still best. Blood, In Press, September 2008.
47. Durie BGM.(Commentary- 25th Year Anniversary Issue) Myeloma therapy: 25 years forward- Immune modulation then and now. J Clin Oncol, In Press, October 2008.

RESEARCH PUBLICATIONS

JOURNALS

1. Durie BGM, Stroud JD, Kahn JA: Progressive systematic sclerosis with malignant atrophic papulosis. Arch Dermatol 100:575, 1969.
2. Durie BGM: Computers: Historical review; applications in medicine and hematology Hematol Sem, 6:543-553, 1970.
3. Durie BGM, Peters GA: Cardiac arrhythmia following a hornet sting. Ann Allergy, 28:569, 1970.
4. Gill W, Carter DC, Durie BGM: Retroperitoneal tumors: A review of 134 cases. J Royal Coll Surg (Edinburgh), 15:213-221, 1973.
5. Durie BGM, Taswell HG: HL-A antigens in myelomonocytic leukemia; results in 95 patients. Transplantation, 6:397-399, 1973.
6. Sieber O, Fulginiti V, Durie BGM, Salmon S: Successful immunological reconstruction in severe combined immunodeficiency disease with transplantation from a non-compatible donor. Clin Res 14:193, 1973.

7. Durie BGM, Taswell HF: Lymphocyte responses in the Sezary Syndrome (T-cell erythroderma). Archives of Dermatol, 108:205, 1973.
8. Jones SE, Salmon SE, Durie BGM: Failure of indium 111-labeled bleomycin tumor scanning to predict response to bleomycin (NSC-125066) treatment. Cancer Chemother Rep 58 (part 1):733-735, 1974.
9. Durie BGM, Taswell HF: Cell-mediated immunity in patients with myelomonocytic leukemia. J Immunol Meth, 16:331-339, 1974.
10. Salmon SE, Durie BGM: Le myeloma et la macroglobulinemie Idiopathique. Cashiers Integres de Medecine. Hematologie, cancerologie et Immunologie applique. V. Cancerologie (5), Hemopathies Malignes. Masson et Ce, Paris. No. 105, March 9, 1974.
11. Durie BGM, Salmon SE: Evaluation and treatment of multiple myeloma and related disorders. (J. Vaeth, ED.), S. Karger AG, Medical and Scientific Publishers, Basel, Switzerland, Front Radiat Ther Oncol, 10:170-177, 1974.
12. Durie BGM: Therapy of acute leukemia. AZ Med, 31:283-284, 1974.
13. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment and survival. Cancer, 36: 842-854, 1975.
14. Durie BGM, Salmon SE: High-speed scintillation autoradiography. Science 190:1093-1095, 1975.
15. Salmon SE, Durie BGM: Cellular kinetics in multiple myeloma: A new approach to staging and treatment. Arch Int Med, 135:131-138, 1975.
16. Durie BGM, Salmon SE: A clinical staging system for multiple myeloma. A new approach to staging and treatment. Arch Int Med, 135:131-138, 1975.
17. Jones Se, Durie BGM, Salmon SE: Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer. Cancer, 36:90-97, 1975.
18. Durie BGM, Salmon SE: Cellular kinetics, staging and immunoglobulin synthesis in multiple myeloma. Ann Review Med, 26:283-288, 1975.
19. Russell DH, Durie BGM, Salmon SE: Polyamines as predictors of success and failure in cancer chemotherapy. Lancet 2:797-799, 1975.
20. Jones SE, Lilien DL, O'Mara RE, Durie BGM, Salmon SE: Indium-111 bleomycin tumor scanning in lymphoma. Med Ped Oncol 1:11-21, 1975.

21. Jones SE, Lilién DL, O'Mara RE, Salmon SE, Durie BGM: A clinical evaluation of indium-111 bleomycin as a tumor-imaging agent. Cancer 35:1036-1049, 1975.
22. McMahon LJ, Jones SE, Durie BGM, Salmon SE. Combination chemotherapy with methyl-CCNU (NSC-95441), cyclophosphamide (NSC-26271), vincristine (NSC-67574), methotrexate (NSC-740), and bleomycin (NSC-125066), in advanced bronchogenic carcinoma. Cancer Letters 1:97-102, 1975.
23. Kleckner HB, Durie BGM, Schnur PL: Current trends in malignant melanoma. AZ Med, 33:468-470, 1976.
24. Salmon SE, Durie BGM: Application of kinetics to chemotherapy for multiple myeloma. Proceedings 29th annual symposium on Fundamental Cancer Research, (Williams and Wilkins) 865-878, 1976.
25. Lloyd RE, Jones SE, Salmon SE, Durie BGM, McMahon LJ: Combination chemotherapy with adriamycin (NSC-123127), and cyclophosphamide (NSC-26271), for solid tumors: A phase II trial. Cancer Treat Rep 60:77-83, 1976.
26. Alberts DS, Durie BGM, Salmon SE: Doxorubicin/BCNU chemotherapy for multiple myeloma in relapse. Lancet 1:926-928, 1976.
27. Durie BGM, Salmon SE: Multiple myeloma, macroglobulinemia and monoclonal gammopathies. In: Recent Advances in Haematology. (AV Hoffbrand, MC Brain, J Hirsch, Eds). Churchill Livingstone, London, Edinburgh. Chapter 13:243-261, 1977.
28. Durie BGM, Hellman D, O'Mara RE, Woolfenden J, Kartchner M, Salmon SE: Multimodality treatment for high risk thyroid carcinoma. In: Adjuvant Therapy of Cancer (SE Salmon, SE Jones, Eds.) Elsevier/North Holland Press, Amsterdam. Pages 475-486, 1977.
29. Durie BGM, Salmon SE, Russell DH: Polyamines as makers of response and disease activity in cancer chemotherapy. Cancer Res 37:214-221, 1977.
30. Durie BGM, Giles HR: Successful treatment of acute leukemia during pregnancy. Arch Int Med 137:90-91, 1977.
31. Alberts DS, Durie BGM, Salmon SE: Treatment of multiple myeloma in remission with anticancer drugs having cell cycle specific characteristics. Cancer Treat Rep 61:381-388, 1977.
32. Durie BGM: Scintillator distribution in high-speed autoradiography. Science 195:208, 1977.

33. Jones SE, Tucker WG, Haut A, Trantum BL, Vaughn C, Chase EM, Durie BGM: Phase II trial of Piperazinedione in Hodgkin's disease, non-Hodgkin's lymphoma and multiple myeloma: A Southwest Oncology Group Study. Cancer Treat Rep 61:1617-1621, 1977.
34. Salmon SE, Durie BGM: Clinical staging and new therapeutic approaches in multiple myeloma. Recent Results in Cancer Res.,65:12-20, 1978.
35. Durie BGM, Mundy GR, Salmon SE: Osteoclast stimulating factor. Correlation with measured myeloma cell mass and clinical features in patients with multiple myeloma. Calcified Tissues Res Suppl: 319, 1978.
36. Cole PW, Durie BGM, Salmon SE: Immunoquantitation of free light chain immunoglobulins. Applications of multiple myeloma. J Immunol Meth 19:341-349, 1978.
37. Durie BGM, Vaught L, Chen YP, Olson GB, Salmon SE, Bartels PH: Discrimination between T and B lymphocytes and monocytes by computer analysis of digitized data from scanning microphotometry: I. Chromatin distribution patterns. Blood 51:579-589, 1978.
38. Rosenblum MG, Durie BGM, Salmon SE, Russell DH: Metabolism of [¹⁴C]Spermidine [¹⁴C] Putrescine in normal volunteers and in cancer patients. Cancer Res 38:3161-3163, 1978.
39. Salmon SE, Hamburger AW, Soehnien BS, Durie BGM, Alberts DS, Moon TE: Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med 298:1321-1327, 1978.
40. Rosenblum MG, Durie BGM, Beckerman RC, Taussig LM, Russell DH: Cystic fibrosis: Decreased conjugation and excretion of [14C] spermidine. Science 200: 1496-1497, 1978.
41. Russell DH, Rosenblum MG, Beckerman RC, Durie BGM, Taussig LM, Barnett DR: Altered polyamine metabolism in cystic fibrosis. Ped Res 13:1137-1140, 1979.
42. Salmon SE, Alberts DS, Durie BGM, Meyskens FL, Soehnlén BA, Chen H-SG, Moon TE: Clinical correlation of drug sensitivity in the human tumor stem cell assay. Recent Results in Cancer Research Proc. of EORTC Plenary Session on Cancer and Chemo-Immunopharmacology Paris, June 20-22, 1979. Recent results in Cancer Res 74:300-305, 1980.
43. Hellman DE, Durie BGM, Woolfenden JM, Kartchner M: Multi-disciplinary management of carcinoma of the thyroid. AZ Med, 37:19-25, 1980.
44. Levine AS, Durie BGM, Lampkin B, Leventhal BG, Levy HB: Poly (ICLC): Interferon induction, toxicity and clinical efficacy in leukemia, lymphoma, solid tumors, myeloma and laryngeal papillomatosis. Proc 2nd International Conf Immunotherapy of Cancer NCI, NIH, 1980.

45. Durie BGM: The role of polyamines as predictors of success and failure in cancer chemotherapy. (Vol 2:113-122). In: Tumor Progression (Ray G Crispen Ed), Developments in Cancer Research, Elsevier North Holland, Inc., publishers, 1980.
46. Durie BGM: Lambda myelomas. Proceedings of Workshop on Recent Advances and Future Trends in Myeloma. Institut National de la Sante et de La Recherche Medicale, Montpellier, France. Elsevier/North Holland Biomedical Press, 1980.
47. Durie BGM: Labeling indices and prognosis of myeloma. Proceedings of Workshop on Recent Advances and Future Trends in Myeloma. Institut National de la Sante et de la Recherche Medicale, Montpellier, France. Elsevier/North Holland Biomedical Press, 1980.
48. Durie BGM, Salmon SE: Use of Clodronate in the treatment of hypercalcemia in multiple myeloma. Proceedings of Workshop on Recent Advances and Future Trends in Myeloma. Institut National de la Sante et de La Recherche Medicale, Montpellier, France. Elsevier/North Holland Biomedical Press, 1980.
49. Jones SE, Salmon SE, Alberts DS, Meyskens FL, Durie BGM, Chen H-SG: In vitro phase II trial of vinca alkaloids. Proceedings of the International Vinca Alkaloid Symposium-Vindesine, Frankfurt Am, November 1980.
50. Durie BGM, Salmon SE, Moon TE: Pretreatment tumor mass, cell kinetics and prognosis in multiple myeloma. Blood 55:364-372, 1980.
51. Durie BGM, Russell DH, Salmon SE: The plateau phase in multiple myeloma: A reappraisal Lancet 65-68, July, 1980.
52. Bataille R, Durie BGM, Salmon SE: Myeloma bone marrow acid phosphatase staining: A correlative study of 38 patients. Blood 55:802-805, 1980.
53. Woolfenden JM, Platt MJ, Durie BGM, Moon TE: Comparison of bone scintigraphy and radiography in multiple myeloma. Radiology 134:723-728, 1980.
54. Durie BGM, Salmon SE: Therapeutic strategie in multiple myeloma. Bull Cancer (Paris) 64 (4) :450-457, 1980.
55. Durie BGM: Bone marrow transplantation for acute nonlymphoblastic leukemia. N Engl J Med, 302:408, 1980.
56. Garewal H, Durie BGM: Beta₂-Microglobulin: A potentially useful marker for hematologic malignancies. AZ Med, 38:912-913, 1981.
57. Salmon SE, Alberts DS, Meyskens FL, Durie BGM, Jones SE, Moon TE: Tumor cells and adjuvant chemotherapy: Perspectives in 1981. In: Adjuvant Therapy of Cancer III, Grune & Stratton, 13-23, 1981.

58. Durie BGM: Cloning efficiency and monitoring of the chemotherapy of plasma cell myeloma. Ettore Majorana, Centre for Scientific Culture. International School of Medical Sciences. Advances in Lymphoproliferative Disorders, 15th Course: 309:319, 1981.
59. Durie BGM, Salmon SE, Mundy GR: Relation of osteoclast activating factor (OAF) production to the extent of bone disease in multiple myeloma. Br J Haematol 47:21-30, 1981.
60. Durie BGM, Hellman D, O'Mara RE, Woolfenden J, Kartchnet M, Salmon Se: High-risk thyroid cancer. Prolonged survival with early multimodality therapy. Cancer Clin Trials 4:67-73, 1981.
61. Durie BGM, Cole PW, Chen H-SG, Himmelstein KJ, Salmon SE: Synthesis and metabolism of Bence-Jones protein and calculation of tumor burden in patients with Bence-Jones myeloma. Br J Haematol 47:7-19, 1981.
62. Dana B, Durie BGM, White RF, Huestis DW: Concomitant administration of granulocyte transfusions and amphotericin B in neutropenic patients: Absence of significant pulmonary toxicity. Blood 57:90-94, 1981.
63. Hofmann V, Salmon SE, Durie BGM: Drug resistance in multiple myeloma associated with high in vitro incorporation of ³[H]-Thymidine. Blood 58 (3):471-476, 1981.
64. Durie BGM, Valeriote, Phillips, Schiffer: Cancer research impact of the cooperative groups. Basic Res, Masson Publishing, Chapter 20, 361-365, 1981.
65. Moon TE, Salmon SE, White CS, Chen H-SG, Meyskens FL, Durie BGM, Alberts DS: Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy. Cancer Chemother Pharmacol 6:211-218, 1981.
66. Durie BGM: Staging and kinetics of multiple myeloma. In: Clinics in Haematology 11: 181-210, 1982.
67. Durie BGM, Salmon SE: The current status and future prospects of treatment for multiple myeloma. In: Clinic in Haematology 11:181-210, 1982.
68. Durie BGM, Persky B, Soehnlen BJ, Grogan TM, Salmon SE: Amyloid production in human myeloma stem cell culture with morphologic evidence of amyloid secretion by associated macrophages. N Engl J Med 307:1689-1692, 1982.
69. Garewal H, Durie BGM: Aggressive phase of multiple myeloma with pulmonary plasma cell infiltrates. JAMA 348:1875-1876, 1982.

70. Brooks RJ, Dorr RT, Durie BGM: Interaction of allopurinol with 6- mercaptopurine and azathioprine: Case report and review of the literature. Biomedicine 36:217-222, 1982.
71. Herman TS, Durie BGM, Hutter JJ: Treatment of patients with refractory myelogenous leukemia with BCOMM (1, 3-bis-chloro (2-chloroethy1)-1-nitrosourea (BCNU), oncovin (vincristine), cyclophosphamide, high-dose methotraxate and methyl-glyoxal bisquanylhydrazone (MGBG)]. Cancer Chemother Pharmacol 8:73-75, 1982.
72. Ahmann FR, Meyskens FL, Moon TE, Durie BGM, Salmon SE: In vitro chemosensitivities of human tumor stem cells to phase II drug (M. AMSA) 4' - (9-acridinylamino) methanesulfon-m-anisidide and prospective in vivo correlations. Cancer Res 42: 4495-4498.
73. Durie BGM, Young LA, Simon SE: Human myeloma in vitro colony growth: Interrelationships between drug sensitivity, cell kinetics, and patient survival duration. Blood 61:929-934, 1983.
74. Trent JM, Durie BGM, Davis JR, Veomett I: Cytogenetic and clinical assessment of six patients with erythroleukemia. Anticancer Res 3:111-116, 1983.
75. Dana BW, Durie BGM, White RF, Huestis DW, Paplanus S: The significance of pulmonary infiltrates developing in patients receiving granulocyte transfusions. Br J Haematol 53 (3):437- 443, 1983.
76. Trent JM, Davis JR, Durie BGM: Cytogenetic analysis of leukemia colonies from acute and chronic myelogenous leukemia. Br J Cancer 47:103-109, 1983.
77. Salmon SE, Durie BGM, Young L, Liu RM, Trown PW, Stebbing N: Effects of cloned human leukocyte interferons in the human tumor stem cell assay. J Clin Oncol 1:217-225, 1983
78. Ludwig CU, Durie BGM, Salmon SE, Moon TE: Tumor growth stimulation in vitro by interferons. Eur J Cancer Clin Oncol 19:1625-1632, 1983.
79. Salmon SE, Haut A, Bonnet JD, Amare M, Weick JK, Durie BGM, Dixon DO: Alternating combination chemotherapy and levamisole improve survival in multiple myeloma. A Southwest Oncology Group Study. J Clin Oncol 1:453:461, 1983.
80. Boccadoro M, Gavarotti P, Fossati G, Massaia M, Pileri A, Durie BGM: Kinetics of circulating B Lymphocytes in human myeloma. Blood 61:812-814, 1983.
81. Bataille R, Durie BGM, Grenier J: Serum beta-2-microglobulin and survival duration in multiple myeloma: A simple reliable marker for staging. Br J Haematol 55:439-447, 1983.
82. Wirt DP, Grogan TM, Payne CM, Kummet TD, Durie BGM, et al: Phagocytic, lambda light chain, plasma cell myeloma. Am J Clin Path 80:75-84, 1983.

83. Ludwig CH, Hicks MNJ, Pena D, Durie BGM: OKT-8+-suppressor-T-lymphozyten sind bei patienten mit stabilem multiple myelona vermehrt. Schweiz med Wschr 113:1451-1454, 1983.
84. Ahmann FR and Durie BGM: Acute myelogenous leukemia modulated by B12 deficiency: A case with bone marrow blast cell assay corroboration. Br J Haematol 58:91-94, 1984.
85. Durie BGM: New approaches to myeloma colony growth. Proc Int Conf Cell Kinetics and Drug Testing in Oncology (Santa Margh., Italy), 1984.
86. Berdeaux D, Durie BGM: Idiopathic thrombocytopenia purpura (ITP)in pregnancy. Az Med XLI (2) : 240-243, 1984.
87. Durie BGM: The plasma cell diseases. Proceedings of the Eighth Annual Cancer Symposium (San Diego, CA), October, pp. 234-245, 1984.
88. Durie BGM: Multiple myeloma. Current trends and problems in staging and response evaluation. Proceedings Myeloma Symposium, Padua, Italy, April, 1984.
89. Durie BGM: Southwest Oncology group induction protocols for multiple myeloma. Proceedings Myeloma Symposium, Padua, Italy, April, 1984.
90. Durie BGM: Recent advances in multiple myeloma and related monoclonal gammopathies. Current Haematol 3:239-286, 1984.
91. Hutter JJ, Hecht F, Kaiser-McCaw B, Hays T, Baranko P. Cohen J, Durie BGM: Bone marrow monosomy 7: Hematologic and clinical manifestations in childhood and adolescence. Hematol Oncol 2:5-12, 1984.
92. Garewal H, Durie BGM, Kyle RA, Finley P, Bower B, Serokman R: Serum beta-2 microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders. J Clin Oncol 2:51-57, 1984.
93. Durie BGM: Is myeloma really a monoclonal disease? Br J Haematol 57 (3):357-363, 1984.
94. Boccadoro M, Gavarotti P, Fossati G, Pileri A, Marmont F, Neretto G, Gallamini A, Volta C, Trinalto M, Testa MG, Amadori S, Mandelli F, Durie BGM: Low plasma cell ³(H) thymidine incorporation in monoclonal gammopathy of undetermined significance (MGUS) smolering myeloma and remission phase myeloma: A reliable indicator of patients not requiring therapy. Br J Haematol 58:689-696, 1984.
95. Durie BGM: Experimental approaches to drug testing and clonogenic growth: Results in multiple myeloma and acute myelogenous leukemia. Proc Int Conf Predictive Drug Testing on Humans Tumors Cells (Zurich) Recent Results in Cancer Res 94:93-101, 1984.

96. Ahmann FR, Jones SE, Moon TE, Hammond N, Miller TP, Durie BGM: Chemo-hormonal therapy for advanced breast cancer with Tamoxifen, adriamycin, and cyclophosphamide (TAC). Cancer 56:730 - 737, 1985.
97. Durie BGM: Current thinking about the management of multiple myeloma and related disorders. Oncology Mediguide, 5 (2) : 1-5, 1985.
98. Durie BGM: The malignant cell in multiple myeloma and Waldenstroms macroglobulinemia. Proc Europe Symp. Monoclonal Gammopathies: Clinical significance and basic mechanism (Brussels, Belgium), September 1: 25-34, 1985.
99. Dalton WS, Durie BGM: Cell cycle kinetics and applications to cancer chemotherapy. Hospital Therapy, 12:43-49, 1985.
100. Crossen PE, Broderick RD, Durie BGM, Trent JM: Proliferative characteristics and sister chromatid exchange (SCE) of colony-forming cells (CFU-S) in acute myelogenous leukemia. Cancer Genet Cytogenet 14:267-273, 1985.
101. Durie BGM, Vela E, Baum V, Leibovitz A, Payne CM, Richter LC, Grogan TM, Trent JM: Establishment of two new myeloma cell lines from bilateral pleural effusions: Evidence for sequential in vivo clonal change. Blood 66:548-555, 1985.
102. Durie BGM, Grogan TM: CALLA-positive myeloma: An aggressive subtype with poor survival. Blood 66:229-232, 1985.
103. Greenberg BR, Durie BGM, Co Barnett T, Meyskens FL Jr: Phase I-II study of 13-cis-retinoic acid (isotretinoin) in myelodysplastic disorders. Cancer Treat Rep 12:1369-1374, 1985.
104. Durie BGM, Soehnlén BJ, Prudden JF: Antitumor activity of bovine cartilage extract (CATRIX-S) in the human tumor stem cell assay. J Biol Resp Mod 4:590-595, 1985.
105. Ahmann FR, Jones SE, Moot Te, Hammond N, Miller TP, Durie BGM: Chemo-hormonal therapy advanced breast cancer with Tamoxifen, adriamycin, and cyclophosphamide (TAC). Cancer 56:730-737, 1985.
106. Garewel HS, Corrigan JJ, Durie BGM, Jeter MA, Damiano ML: Effect of Danazol on coagulation parameters and bleeding in hemophilia. JAMA 253 (8):1154-1156, 1985.
107. Greenberg BR, Grogan TM, Takasugi BJ, Trent JM, Hicks MJ, Durie BGM: A unique malignant T-cell lymphoproliferative disorder with neutropenia stimulating hairy cell leukemia. Cancer 56:2823-2830, 1985.
108. Kronland R, Grogan T, Spier C, Wirt D, Rangel C, Richter L, Durie BGM, Greenberg B, Miller T, Jones S: Immunotopographic assessment of lymphoid and plasma cell malignancies in the bone marrow. Hum Pathol 16:1247-1254, 1985.

109. Durie BGM: The role of interferons in multiple myeloma. Interferon Letter II (3):5, 1985.
110. Durie BGM: Studies with interferons in the human tumor assay system. Interferon Letter II (3):1, 1985.
111. Garewal HS, Durie BGM: Anti-fibrinolytic therapy with aminocaproic acid for control of bleeding in thrombocytopenia patients. Scan J Haematol, 35:497-500, 1985.
112. Durie BGM, Levy HB, Voakes J, Jett JR, Levine AS: Poly (I,C)-LC as an interferon inducer in refractory multiple myeloma. J Biol Resp Mod 4:518-524, 1985.
113. Garewal Hs, Corrigan JJ, Jeter MA, Damiano ML, Durie BGM: Danazol induced factor VIII and IX bypassing activity in hemophiliacs.
114. Durie BGM, Clouse L, Braich T, Grimm M, Robertone AB: Alpha-2b-interferon/cyclophosphamide combination studies: In vitro and phase I clinical results. Sem Oncol 3 Suppl: 84-88, 1986.
115. Pond GD, Dean JC, Durie BGM, Brumbaugh P: Experience with intra-arterial adriamycin as part of combination therapy for extremity sarcoma. Cancer Chemother Rep, 11:162-169, 1986.
116. Cole PW, Durie BGM, Meezan E, Brendal K, Salmon SE: Inhibition of p-Paminohipurate transport in isolated rabbit renal tubules by free light chain immunoglobulins from patients with Fanconi syndrome and multiple myeloma. Nephron 6:29-36, 1986.
117. Crossen PE, Durie BGM, Trent JM: Generation time (GT) of human bone marrow cells cultured in the CFC-GM assay. Cell Tissue Kinetics,19:533-538, 1986.
118. Berdeaux DH, Glasser L, Serokamnn R, Moon T, Durie BGM: Hypoplastic acute leukemia: Review of 70 cases with multivariate regression analysis. J Hematol Oncol, 4:291-305, 1986.
119. Bataille R, Durie BGM, Grenier J, Sany J: Prognostic factors and staging in multiple myeloma: A reappraisal. J Clin Oncol, 4:80-87, 1986.
120. Durie BGM, Dixon B, Carter S, Stephens R, Bonnet J, Morrison F, Costanzi J, Salmon SE: Improved survival duration with combination chemotherapy induction for multiple myeloma: A Southwest Oncology Group Study. J Clin Oncol, 4:1127-1237, 1986.
121. Fielder K, Durie BGM: Primary amyloidosis associated with multiple myeloma: Predictors of successful therapy. AM J Med 80:413-418, 1986.

122. Dalton WS, Durie BGM, Alberts DS, Gerlack JH, Cress AE, Ling V: Characterization of a new drug resistant human myeloma cell line which expresses P-glycoprotein. Cancer Research, 46:4125-5130, 1986.
123. Durie BGM: Staging and kinetics of multiple myeloma. Sem Oncol 13:300-309, 1986.
124. Kingsley EC, Durie BGM: Prolonged survival in patients with treatment related leukemia. Scan J Haematol 37:103-105, 1986.
125. Durie BGM, Kyle R, Barlogie B: Supportive care management, induction treatment and salvage therapy for multiple myeloma. Blood suppl. (p19-24) Dec. 1986.
126. Lippman SM, Durie BGM, Garewal HS, Giordano G, Greenberg BR: Efficacy of danazol in pure red cell aplasia. Am J Haematol 23: 373-379, 1986.
127. Witte RS, Koeller J, Davis TE, Benson AB, Durie BGM, Lipton A, Stock JL, Citrin DL, Canfield RE: Clodronate: A randomized placebo-controlled double-blind study in the treatment of malignancy associated hypercalcemia. Arch Int Med 147:937-939, 1987.
128. Durie BGM: Plasma cell neoplasms: current status. FACP Symposium Proceedings. Sept. 1987 (p 94-99).
129. Durie BGM: Plasma cell neoplasms; a review. Cancer Medicine. (Harvard, Boston) Sept. 1987 (p 94-99).
130. Durie BGM, Vela EE, Payne CM: Direct secretion of amyloid by myeloma cells. Proc Int Amyloid Symp., 44-46, 1987.
131. Lippman SM, Grogan TM, Spier CM, Koopmann CF, Gall EP, Shimm D, Durie BGM: Lethal midline granuloma with a novel T-cell phenotype as found in peripheral T-cell lymphoma. Cancer 59:936-939, 1987.
132. Grogan TM, Durie BGM, Lomen C, Spier C, Nagle R, Wilson G, Richter L, Vela E, Maxey V, McDaniels K, Rangel C: Delineation of a novel pre-B cell component in plasma cell myeloma: Immunochemical, immunophenotypic, cytologic, cell culture and kinetic features. Blood 70:932-942, 1987
133. Villar H, Warneke J, Peck M, Durie BGM, Bjelland J, Hunter T: Gastrointestinal complications in leukemic patients. Surgery, Gynecology & Obstetrics, 165:217-222, 1987.
134. Durie, BGM: Immunofluorescence method improves clinical utility of myeloma cell labeling indices. Mayo Clinic Proceedings, 62:1027-1058, 1987.
135. Garrett I, Durie BGM, Nedwin G, Gillespie A, Bringman T, Sabatini M, Bertolini D, Mundy G: Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. New Engl J Med, 317:526-532, 1987.

136. Villar H, Warneke J, Peck M, Durie BGM, Bjelland J, Hunter T: Role of surgical treatment in the management of complications of the gastrointestinal tract in patients with leukemia. Surgery, Gynecology & Obstetrics, Vol. 165:217-222. September, 1987.
137. Buzaid AC, Garewal SH, Lippman SH, Durie BGM, et al: Danazol in the treatment of myelodysplastic syndromes. Eur J Haematol 39:346-347, 1987.
138. Boccadoro M, Durie BGM, Frutiger Y, Gavarotti P, Redoglia V, Massaia M, D'Alberto M, Marmont F, Gallamini A, Tribalto M, Pileri A: Lack of correlation between plasma cell thymidine labeling index and serum Beta-2-microglobulin in monoclonal gammopathies. Acta Haemat, 78:239-242, 1987.
139. Kummet TD, Durie BGM: IgM monoclonal gammopathies: A review of the Arizona experience, with emphasis on Waldenstrom's macroglobinemia. W. Med J 145:299-306, 1987.
140. Durie BGM, Christiansen JA: Critical determinants of human myeloma colony growth: The major role Ia antigen positive macrophages. Stem Cells, 4:187, 1987.
141. Ludwig R, Ludwig CU, Owens B, Christiansen JA, Durie BGM: Improved cytochemical and immunofluorescent evaluation of human tumor colonies grown in soft agar. Stem Cells, 4:324, 1987.
142. Villar HV, Ranne RD, Dunnington GL, Jones, SE, Durie BGM, Miller TP, Grogan TM, Wangenstein SL: The role of splenectomy in the management of hematologic diseases. Am J Surgery, 73:43-48, 1988.
143. Durie BGM, Payne C: Unusual membrane abnormalities in a family with congenital dyserythropoetic anemia (CDA). Blood, 66:100, 1985.
144. Rossi JF, Durie BGM, Marion SL, Pike JW, Bataille R, Haussler M, Janbon C: 1,25 - Dihydroxyvitamin D3 - Receptor mediated differentiation of the human myeloma cell line RPMI 8226: Phenotypic and functional analysis. Cancer Research, 48:1213-1216, 1988.
145. Garewal H, Durie BGM: High dose-cytosine arabinoside, daunomycin and 6-thioguanine for relapsed acute non-lymphocytic leukemia. Clinic Res, 32:34, 1984.
146. Kingsley EC, Durie BGM, Garewal HS: Acute promyelocytic leukemia. Western J Med, 146:322-327, 1988.
147. Durie BGM, Dalton WS: Reversal of drug-resistance in multiple myeloma with verapamil. Brit J Haemat, 68:203-206, 1988.
148. Danel V, Bataille R, Roussett F, Durie BGM, Revillard J: Expression of estrogen and progesterone receptors by some human and murine myelomatous cell lines. J Biochem, 34:111-119, 1988.

149. Buzaid A, Durie BGM: Management of refractory myeloma. J Clin Onc, Vol 6, No. 5, May 1988 (889-905).
150. Durie BGM: The biology of multiple myeloma. Proceeding Blenheim Palace myeloma workshop. Oxfordshire, U.K., 24-26 October, 1987. Hematological Oncology, Vol 6, No 2, (p 77-83) April-June 1988.
151. Durie BGM: Chemotherapy of myeloma: SWOG studies. Proceedings Blenheim Palace myeloma workshop, Oxfordshire, U.K., 24-26 October, 1987 Hematological Oncology, Vol 6, No 2, (p 141-145) April-June 1988.
152. Grogan Tm, Durie BGM, Spier CM, Richter L, Vela E: Myelomonocytic antigen positive multiple myeloma. Blood, 73:3:763-769 Feb 15, 1989.
153. Dupperay C, Klein B, Durie BGM, Zhang X, Jourdan M, Poncelet P, Favier F, Vincent C, Brochier J, Lenoir G, Bataille R: Phenotypic analysis of human myeloma cell lines. Blood, 73:566-572, 1988.
154. Bataille R, Durie BGM, Klein B: Antibody specificity of the human monoclonal immunoglobulins: The elusive target antigen. Autoimmunity, 4:181-189, 1989.
155. Durie BGM, Vela E, Frutiger Y, Grogan T: Cross correlation between ³[H] thymidine, BU-1 and Ki-67 assessment of S-phase in multiple myeloma. Proc. 13th Int. Symp. Padua: 43, 1989.
156. Durie BGM: Development of high titre antibodies with roferon (α_2) interferon in hairy cell leukemia: subsequent response to natural leukocyte interferon. Int. Letters: 8:4, 1989.
157. Durie BGM, Haum VE, Vela E, Mundy GR: Abnormalities of chromosome 6q and TNF (lymphotoxin or OAF) production in multiple myeloma. Proc. Cytog. Symp., 4:11, 1989.
158. Durie BGM: Classification of low grade versus high grade myeloma. Proc. 13th Scripps Cancer Symp. 43-46, 1989.
159. Durie BGM, Grogan TM, Spier C, Vela E, Baum V, Rodriguez MA, Frutiger Y: Myelomonocytic myeloma cell line (LB84-1). Blood, Vol 73, No 3, Feb 15 1989 (p770-776).
160. Dalton WS, Grogan TP, Meltzer OS, Scheper RJ, Durie BGM, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol, 7:415-424, 1989.
161. Hicks MJ, Durie BGM, Slymen DJ: Low circulating T-Helper Cells in Relapsing Multiple Myeloma. J Clin Lab Anal, 3:202-208, 1989.
162. Hoyt RH, Durie BGM: Pseudothrombocytopenia induced by a Monoclonal IgM kappa platelet agglutinin. Amer J Haem, 31:50-52, 1989.

163. Bataille R, Durie BGM, Klein B: Antibody specificity of the human monoclonal immunoglobulins: the elusive target antigen. Autoimmunity, 4:181-189, 1989.
164. Bataille R, Klein B, Jourdan M, Rossi JF, Durie BGM: Spontaneous secretion of tumor necrosis factors-beta by human myeloma cell lines. Cancer, 63:877, 1989.
165. Durie BGM, Bataille R: Therapeutic implications of myeloma staging. Eur J Haematol, 51:111-116, 1989.
166. Rossi JF, Durie BGM, Duperray C, Braich T, Samuel L, Marion J, Pike W, Haussler M, Janbon C, Bataille R: Phenotypic and functional analysis of 1,25-Dihydroxyvitamin D3 receptor mediated modulation of the human myeloma cell line RPMI 8226. Cancer Research, 48:1213-1216, 1989.
167. Bataille R, Klein B, Jourdan M, Ross JF, and Durie BGM: Spontaneous secretion of tumor necrosis factor- β by human myeloma cell lines. Cancer 877-880. 1989
168. Durie BGM, Stock-Novack D, Salmon SE, Finley P, Beckord J, Crowley J, Coltman C: Prognostic value of pretreatment serum β_2 microglobulin in myeloma: A Southwest Oncology Group Study. Blood, 75:823-830, 1990.
169. Durie BGM: Interferons in the treatment of myeloma. J Clin Oncol, 2:14, 1990.
170. Spier CM, Grogan A, Durie BGM, Richter LC, Vela E, Frutiger Y, Rangel CS: T-Cell antigen-positive multiple myeloma. Modern Pathology, 3:302-307, 1990.
171. Durie BGM, Dodd-Taylor S: Remarkable efficacy of every other day oral prednisone in drug refractory myeloma. Clinic Res., 36:148, 1990.
172. Van Camp B, Durie BGM, Spier C, De Waele M, Van Riet I, Vela E, Frutiger Y, Richter L, Grogan T: Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1;Leu-19). Blood, 76:377-382, 1990.
173. Durie BGM: Reversal of Drug Resistance with Verapamil in Multiple myeloma. Brit J Haematol, 76:155-156, September 1990.
174. Durie BGM, Vela EE, Frutiger Y: Macrophages as an Important Source of Paracrine IL-6 in Myeloma Bone Marrow. Current Topics in Microbiology & Immunology, 166:33-36, 1990
175. Durie BGM: Serum Beta-2 microglobulin (B₂M) in myeloma (MM): towards a simple prognostic stratification using B₂M and acute phase proteins? Blood, 77:1616-1617, 1991.
176. Durie BGM: New biologic observations and the pathogenesis of multiple myeloma. Proc. IIIrd Int. Myeloma Workshop, 15-17, 1991.

177. Grogan T, Durie BGM, Scheper R, Dalton B: Altered Cell Adhesion Molecule (CAM) Expression Associated with Tumorigenicity in Plasma Cell Myeloma. Proc. IIIrd Int. Myeloma Workshop, 77, 1991.
178. Samson D, Bird J, Newland AC, Joyner M, Durie BGM: A Randomized study comparing VAP and Concurrent Interferon with VAD Followed by IFN Maintenance as First Line Therapy in Newly Diagnosed Myeloma: Preliminary Results. Proc. IIIrd Int. Myeloma Workshop, 100-102, 1991.
179. Durie BGM: Is magnitude of initial response predictive for survival in multiple myeloma? Annals of Oncology, 2:167, 1991.
180. Bataille R, Boccadoro M, Klein B, Durie BGM, Pileri A: C-Reactive Protein and B-2 Microglobulin Allow a Simple and Powerful Myeloma Staging System. Blood, 1992.
181. Durie BGM, Crowley J, Coltman C, Chapman R, Balcerzak S, Bonnet J, Lipschitz D, Stephens R, Cheson B: Phase II evaluation of bisantrene in refractory multiple myeloma, a Southwest Oncology group study. Invest. New Drugs; 1991.
182. Durie BGM: The biology of interleukin 6: The role in plasma cell diseases.. Annals of Oncology, 2:2:208-209, 1991.
183. Durie BGM, Vela EE, Baum V, Frutiger Y: Cytogenetics in multiple myeloma: a review of findings in 130 patients. Proceedings B Cell Neoplasia, 7:161-172, 1991.
184. Durie BGM: What is Multiple Myeloma? Myeloma Today. Volume 1, Number 1, Pages 1-3, 1992.
185. Durie BGM: The Role of Transplantation in Multiple Myeloma. Myeloma Today. Volume 1, Number 3, Pages 1-3, 1993.
186. Durie BGM: What causes Myeloma? Myeloma Today, Volume 1, Number 5, Page 1, 1993.
187. Sonneveld P, Durie BGM, Lokhorst HM, Frutiger Y, Schoester M, Vela EE: Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma. Brit J Haematol, 83:63-67, 1993.
188. Rodriguez MA, Durie BGM, Richter L, Hicks MJ, Grogan TM: Immunohistologic studies of bone marrow accessory cell populations in patients with multiple myeloma: Correlations with prognostic parameters. Leukemia, 16:199, 1993.
189. Durie BGM: What causes myeloma: analysis of IMF database. Proc. Int. Myeloma Symp., 10:432, 1994.
190. Huestis DW, Rifkin RF, Durie BGM, Sibley WA, Irani M: An unexpected complication following immunoabsorption with a staphylococcal protein A column. A.J. Neuro, 79:119, 1994.

191. Durie BGM: What's New in Myeloma Research. Myeloma Today, Volume 1, Number 9, Page 3, 1994.
192. Durie BGM: Inserm - Proceedings of Multiple Myeloma, From Biology to Therapy - Current Concepts. 24-26 Octobre 1994 - Mulhouse, France.
193. Durie BGM: Bone disease in myeloma. Myeloma Today, Volume 1, Number 6, pages 3-4, 1994.
194. Mills D, Durie BGM, Grogan TM, Vela EE, Frutiger Y: Expansion of tumor infiltrating lymphocytes with cytotoxic activity (early CD8⁺, CD11^{b-} and late CD3⁺, CD56⁺) from multiple myeloma bone marrow using IL-2 and LAK supernatant. Int. J. Immunol, 44:109, 1995.
195. Hagin G, Durie BGM: Idiopathic thrombocytopenic purpura: A review of the Arizona experience. Arizona Medical Journal, 21:6, 1995.
196. Durie BGM: What's New - Myeloma Specific Immune Transfer. Myeloma Today, Volume 1, Number 10, 1995.
197. Modiano MR, Durie BGM, Seeger JF: Magnetic resonance imaging in myeloma: A promising tool for diagnosis, staging and follow up. Ariz. Med J. 23:14. 1996.
198. Durie BGM: What's New - Review of Recent Research. Myeloma Today Volume 2, Number 1, 1996.
199. Durie BGM: Inserm Proceedings - The Biology of Multiple Myeloma, Brian G.M. Durie, M.D., Scientific Director, International Myeloma Foundation (IMF), Los Angeles, CA 90046.
200. Durie BGM: Myeloma - 30 Years Forward Where to Now? Proceedings Arosa Myeloma Meeting, January 31, 1996.
201. Durie BGM: Role of PSSC: 833 In Reversing Multi-drug Resistance in Myeloma Proceedings Denver Myeloma Mtg., May 1996.
202. Durie BGM, Gale PR, Horowitz M: IBMTR Experience with Allogenic Transplantation for Multiple Myeloma, PROC. Ann. Symp. 1996.
203. Durie BGM, Gale PR, Horowitz M: IBMTR Twin Transplant Results, PROC Ann. Symp. 1996.
204. Durie BGM, Vela EE, Knight I, Giles F: Significance of serum IL-6 levels in myeloma and MGUS: An analysis in 136 patients. Europ. Journal of Clin. Onc. 32:364. 1996.
205. Durie BGM, Mason DY, Giles F, Vela EE, Knight I, Wolff S, Foadi M, Samson D: Expression of BCL-2 oncogene protein in multiple myeloma. B. J. Onc. 14:319 1996.

206. Durie BGM: et al. Combined single cell testing for growth fraction (L1%) and Bcl-2 oncoprotein in myeloma. Leukemia Research. 13:114, 1997.
207. Durie BGM, Waxman A: Clinical Utility of MIBI Bone Scanning in Myeloma. PROC. Int. Myeloma Workshop, 1997.
208. Ludwig H, Fritz E, Nueda J, Durie BGM: Patient preferences for Interferon alpha in multiple myeloma. J. Clin. Onc. 15:1672,1997.
209. Durie BGM, Waxman A: FDG/PET scanning in multiple myeloma. PROC. Int. Soc Nuc Med. 4:111, 1997.
210. Gale RP, Durie BGM: Delphi-panel analysis of appropriateness of high dose therapy and bone marrow autotransplants in newly diagnosed multiple myeloma. Leukemia and Lymphoma. 48:119, 1998.
211. Durie BGM, Urnovitz H: Expression of DU ALU RNA in the plasma of patients with active myeloma. Leukemia. 46: 13-17, 1998
212. Durie BGM, Urnovitz H: Biaxin (Clarithromycin) as treatment for multiple myeloma. PROC. Chemo. Found. Symposium. New York. XVI: 88-89, 1998.
213. Durie BGM, Urnovitz H: Active ALU sequences and the evolution of myeloma. Nat. Genetics, 4: 111, 1998.
214. Durie BGM, Martin J: Stealth viruses and active myeloma: clinical correlations. Lancet, Vol: 131-134, 1998.
215. Durie BGM, Damiano ML, Corrigan J, Volz R: Use of autoplex for successful bilateral knee replacement in a hemophiliac with high tire inhibitor. Med Ped Onc. 4: 113-116, 1998.
216. Durie BGM: A role for complementary medicine in myeloma care. Myeloma Today. Vol 3, No 1: 3-4, 1998.
217. Gillespie TJ, Durie BGM, Garewal H, Davis TP: Analysis of D-Arabitonol, an indicator of invasive candidiasis in leukemia patients, by gas chromatography/mass spectrometry. Pharmacology. 6: 206-210, 1998.
218. Rodriguez MA, Meltzer PS, Durie BGM: Presence of Epstein-Barr virus in plasma cells of human multiple myeloma. Onc Res. 16: 11-15, 1998.
219. Durie BGM, Rodriquez MA: Predictors of long term relapse free survival in multiple myeloma. Acta Haemat. 38: 101-106, 1998.
220. Durie BGM, Bataille R: What causes myeloma? Proc Myeloma Symp. Nantes, France. September 1-6, 1998.
221. Durie BGM: Thalidomide: Is it for you? Myeloma Today. Vol 3, No 3: 5-6, 1998.

222. Croghan M, Durie BGM, Dalton W, Vela E, Tu F: Paradoxical increased sensitivity of chemotherapy-resistant myeloma cells to biologic agents and corticosteroids. J Clin Pharm. 31: 46-49, 1998.
223. Meltzer P, Shadle K, Durie BGM: Somatic mutation alters a critical region of the C-MYC gene in multiple myeloma. Canc. Res. 57: 107, 1998.
224. Durie BGM: Steroids: Why we love them, hate them, need them. Myeloma Today. Vol 3, No 4: 7-8, 1999.
225. Durie BGM: What is STAT 3: Is it important? Myeloma Today. Vol 3, No 4: 8, 1999.
226. Durie B, Urnovitz J. Cell and molecular biology of simian virus 40: Implications for human infections and disease. J Nat Ca Instut. 91(13):1166-1167, 1999.
227. Durie BGM: Tour de France Victory: Can it become a Tour de Force? Myeloma Today. Vol 3, No 6: 3, 1999.
228. Durie BGM: What's new on the horizon for myeloma? Myeloma Today. Vol 3, No 7: 5, 1999.
229. Durie BGM, Urnovitz HB, Murphy WH: RT-PCR amplicons in the plasma of multiple myeloma patients, clinical relevance and molecular pathology. Acta Oncologica. 39 (No. 7): 789-796, 2000.
230. Durie BGM: Multiple myeloma: sliding scale therapeutics: prescriptions and recommendations. Onc Economics, 8: 15-16, 2000.
231. Durie BGM, Stepan DE: Efficacy of low dose thalidomise in multiple myeloma. Elec J Onc, 2000, 1, 1-8. Available at www.Eleccioncol.org/ejo/cgi-bin/Escripts2000.pl
232. Durie BGM: The real world costs of multiple myeloma. Onc Spec, Vol 2, No 3: 86-93, 2001.
233. Durie BGM: Myeloma in the millennium: Outcomes of the IMF myeloma think tank 2000. Myeloma Today, Vol 4, No 3: 1-3, 2001.
234. Durie BGM: Multiple myeloma: What's new?. CA Cancer J Clin, 2001; 51: 271-272.
235. Durie BGM: Myeloma: What's new? Myeloma Today, Vol 4, No 3: 6, 2001.
236. Durie BGM: Seventh International Myeloma Workshop: Meeting report from Banff, Canada. May 4th-8th, 2001. Myeloma Today, Vol 4, No 5: 1-3, 2001.
237. Durie, BGM: Proceedings of the First International Myeloma Symposium. St. Petersburg, Russia. Myeloma Today, Vol 4, No 5: 7-9, 2001.

238. Durie BGM: Drug interactions with citrus fruits. Myeloma Today, Vol 4, No 7: 5, 2001.
239. Durie BGM: The epidemiology of multiple myeloma. Seminars in Hematology, Vol 38, No 2, Suppl 3: 1-5, 2001.
240. Durie BGM: Thalidomide: clinical outcomes. VIIIth International Myeloma Workshop, Banff, Canada, 2001.
241. Durie BGM: Cellular genetics of myeloma. Proc Int Myeloma Symp, Istanbul, Turkey. June 2001, 1: 11-13.
242. Durie BGM: Advances in treatment of multiple myeloma. Aust Med J, 17: 104-110, 2001.
243. Durie BGM: International myeloma grand round. Lancet Oncology, Sept 2001.
244. Durie BGM: Deep in the bone, managing multiple myeloma. Cure, Vol 1, No 2, 2002.
245. Durie BGM: ASH 2001. Myeloma Today, Vol 4, No 8: 1-3, 2002.
246. Durie BGM: The "Myeloma Matrix". Myeloma Today, Vol 4, No 9: 1, 2002.
247. Durie BGM: Infection in myeloma. Myeloma Today, Vol 4, No 9: 3, 2002.
248. Durie BGM: The importance of knowing the potential outcome. Myeloma Today. Vol 4, No 10: 1-3, 2002.
249. Durie BGM: Outcomes of the IMF St. John's retreat: Myeloma management guidelines. Myeloma Today, Vol 5, No 1: 1-3, 2002.
250. Greipp PR, San Miguel JF, Durie BGM: Development of an international prognostic index (IPI) for myeloma: report of the international myeloma working group. The Hem J, Vol 4, Suppl 1: 71, 2003.
251. Durie BGM, Katz MS: Interactive computer program reveals current disease features and patterns of myeloma management. The Hem J, 4, Suppl 1: 211, 2003.
252. Durie BGM, Gabayan E, Stepan DE: Low dose thalidomide plus dexamethasone schedules produce equivalent results with less toxicity than higher doses in both frontline and relapse myeloma. The Hem J, 4, Suppl 1: 325, 2003.
253. Supreme Court of the United States Amici Curiae Brief: Dow Chemical Company, Monsanto Company, et al, petitioners, v. Stephenson, Isaacson, respondents. Brief Amici Curiae of the Lymphoma Foundation of America, Cranor CF, Davis D, Defur PL, Durie BG, Lockwood AH, Ozonoff D, Schechter AJ, and Wallinga D, in support of respondents. No. 02-271. Submitted and published May 2003.

254. Durie BGM, Waxman AD, D'Agnolo A, et al. 99m Tc-MIBI and 18F-FDG PET imaging in multiple myeloma. J Nucl Med, 44: 632-634, 2003.
255. Kumar A, Loughran T, Alsina M, Durie BGM. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncology, 4: 293-304, 2003.
256. Durie BGM: Low-dose thalidomide in myeloma: efficacy and biologic significance. Seminars in Oncology, 29 (No 6, Suppl 17): 34-38, 2002.
257. Durie BGM, Waxman AD, D'Agnolo A, Williams CM: Whole-body 18F-FDG PET identifies high-risk myeloma. J Nucl Med 2002; 43: 1457-1463.
258. Criteria for the classification of monoclonal gammopathies, multiple myeloma, and related disorders: a report of the International Myeloma Working Group. Br J Haematol, 121: 749-757, 2003.
259. Jacobson J, Huseein MA, Durie BGM, et al: A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience. Br J Haematol., 122: 441-450, 2003.
260. Durie BGM, Kyle R, Bensinger W, et al: Myeloma Management Guidelines, a consensus report from the scientific advisors of the International Myeloma Foundation., Haematology Journal, Vol 4: 379-398, 2003.
261. Durie BGM. Monitoring Multiple Myeloma with FDG/PET. Radiology Today, 4 (No. 2): 20-23, 2003.
262. Durie BGM: Multiple myeloma, cancer of the bone marrow. IMF Concise Review of the disease and treatment options. 2004 Edition.
263. Durie BGM, Jacobson J, Barlogie B, et al. Time to progression, but not magnitude of regression predicts survival benefit in SWOG standard dose chemotherapy studies for multiple myeloma. J. Clin Onc, 22: 1857-1963, 2004.
264. Greipp PR, San Miguel J, Durie BGM, et al. An International Staging System for Multiple Myeloma. J. Clin Onc, 23 (15): 3412-3420, 2005.
265. Jagannath S, Durie BGM, Wolf J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Brit J Haem, 129:776-783, 2005.
266. Durie BGM, Katz M, McCoy J, et al: Osteonecrosis of the jaw and bisphosphonates. New Eng. J. Med, Jul 7, 353(1): 99-102, 2005.
267. Durie BGM. New Approaches to Treatment for Multiple Myeloma: Durable Remission and Quality of Life as Primary Goals. Clin Lymphoma Myeloma, 6 (3): 181-90, 2005.

268. Durie BGM, Harousseau JL, et al. International uniform response criteria for multiple myeloma. Leukemia, 20:1467-1473, 2006.
269. Durie BGM. The role of anatomic staging in myeloma: Description of Durie/ Salmon plus staging system. European Journal of Cancer, 42 (11): 1539-43, 2006.
270. Barlogie B, Kyle RA, Durie BGM, et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. JCO, Feb 20: 929-936, 2006.
271. Zonder JA, Barlogie B, Durie BG, et al. Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis. Blood, 108(1): 403, 2006.
272. Durie BG, Attal M, Beksac M, et al. Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement. Mayo Clin Pro, 82:516-522, 2007.
273. Spisek R, Kukreja A, Chen L, Durie B, et al. Frequent and specific immunity to the embryonal stem cell associated antigen SOX2 in patients with monoclonal gammopathy. J Experimental Med, 204(4): 831-840, 2007.
274. Durie BGM. Novel approaches to myeloma therapy: The role of newer Anthracycline-containing regimens. Clin Lymph & Myeloma, 7(S4):S138, 2007.
275. Durie BGM, Rajkumar SV. (Letter to Editor) Assessing response rates in clinical trials of treatment for relapsed or refractory multiple myeloma: a study of bortezomib and thalidomide by H Prince, Brad Schenkel and Linda Mileschkin. Leukemia, 21:821, 2007.
276. Durie BGM. The importance of the new international uniform response criteria for multiple myeloma. Am J Hemat Oncol, 6(5)S7:15-18, 2007.
277. Durie BGM. Baseline serum free light chain testing provides important prognostic data in multiple myeloma. The Binding Site: Freelite Update, 1(2):1-3, 2007.
278. Stadtmauer EA, Lonial S, Vesole DH, et al. A practice guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceeding. Clin Adv Hematol Oncol, 5(10 S15):7-19.
279. Anderson KC, Kyle RA, Rajkumar SV, et al. Clinically relevant end points and new drug approvals for myeloma. Leukemia 22:231-239, 2008.
280. Hungria VTM, Maiolino A, Martinez G, et al. Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma. Haematologica, 93(5):791-792, 2008.
281. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia, 22:414-423, 2008.

282. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma Working Group. Blood, 111:4039-4047, 2008.
283. Durie BGM. (Editorial) Oncology nurses take the lead in providing novel therapy guidelines for multiple myeloma. Clin J Oncol Nurs 12(3)S:7-8, 2008.
284. Rajkumar SV, Durie BGM. Eliminating the complete response penalty from myeloma response criteria. Blood, 111(12):5759, 2008.
285. Hussein MA, Vrionis FD, Allison R, et al. The role of vertebral augmentation in multiple myeloma: International myeloma working group consensus statement. Leukemia advance online publication; doi:10.1038/leu.2008.127, May 29, 2008.

SUBMITTED OR IN PRESS

286. Hussein M, Bolejack V, Zonder J, Durie B, et al. Phase II study of thalidomide plus dexamethasone induction followed by tandem melphalan-based autotransplantation and thalidomide-prednisone maintenance for untreated multiple myeloma: a Southwest Oncology Group trial (S0204). Blood, Submitted July 2008.
287. Ludwig H, Anderson KC, Dammacco F, et al. ESAs not the culprit: More studies required. Am J Hemat Oncol, In Press, August 2008.
288. Durie BGM, Van Ness B, Ramos C, et al. Genetic polymorphisms identify the likelihood of bone disease in myeloma: Correlations with myeloma cell DKK1 expression and high risk gene signatures. Leukemia, Submitted, August 2008.
289. Van Ness B, Ramos C, Haznadar M, et al. Genomic variation in myeloma: Design, content, and initial application of the Bank on a Cure SNP panel to analysis of survival. BMC Medical Genet, In Press, August 2008.
290. Johnson DC, Corthals S, Ramos C, et al. Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping, Blood, In Press, 2008.
291. Durie BGM. (Editorial) Treatment of myeloma- Are we making progress?. New Engl J Med, In Press, August 2008.
292. Zonder JA, Crowley J, Hussein MA, et al. S0232: Dex +/- lenalidomide for previously untreated myeloma- updated results. Blood, Submitted, 2008.
293. Durie BGM. (Commentary) Crossover confusion: MPT still best. Blood, In Press, September 2008.

294. Durie BGM.(Commentary) Myeloma therapy: 25 years forward- Immune modulation then and now. J Clin Oncol, In Press, October 2008.
295. Dispenzieri A, Kyle R, Merlini G, et al. International myeloma working group guidelines for serum free light chain analysis in multiple myeloma and related disorders. Leukemia, Submitted, 2008.
296. Kyle RA, Boccadoro M, Rajkumar SV, Durie BGM. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: Risk factors for progression. In Preparation, 2008.
297. Giralt S, Harousseau JL, Palumbo A, et al. International myeloma working group consensus statement on the role of plerixafor in stem cell harvesting. In Preparation, 2008.
298. Fonseca R, Avet-Loiseau H, et al. International myeloma working group genetic classification of myeloma. In Preparation, 2008.
299. Kumar S, et al. International myeloma working group consensus statement on the risk factors for stem cell harvesting in myeloma. In Preparation, 2008.
300. Ludwig H, Durie BGM, Bolejack V, et al. Myeloma long term survival: Calculation of potential life-years lost: An analysis of 10,549 patients from the International Myeloma Working Group. In Preparation, 2008.
301. Jagannath S, Durie BGM, et al. Long-term follow up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma: Impact of initial autologous stem cell transplantation, In Preparation, 2008.
302. Durie BGM, Urnovitz H, et al. Circulating nucleic acids in multiple myeloma: presence of non-coding/intergenic DNA reflects disease activity. In Preparation, 2008.

CHAPTERS

1. Durie BGM: Therapy of multiple myeloma. In: Current Therapy (Ed. By HF Conn), WB Saunders Co., Philadelphia, 326-328, 1978.
2. Durie BGM, Russell DH: Polyamines as tumor markers. In: Tumor Markers: Impact and Prospects, Elsevier/North Holland Biomedical Preast 1979.
3. Durie BGM: Kinetic studies in myeloma and their implications for treatment. In: Principles of Cancer Treatment, Ed. by Carter SK, Glatstain E, Livingstone RB. McGraww-Hill Book Co., 1980.
4. Durie BGM: Polyamines and cancer therapy. In: Polyamines in Biomedical Research. Ed. by JM Caugus, John Wiley & Sons LTD, 1980.

5. Durie BGM: Cell kinetic analysis of human tumor stem cells. In: Chapter 13: Cloning of Human Tumor Stem Cells, Alan R Liss, Inc., New York, pp 153-163, 1980.
6. Durie BGM: Multiple myeloma. Current concepts in the use of Doxorubicin Chemotherapy, Farmitalia, Ed. Stephen Jones, 95-101, 1982.
7. Durie BGM: Acute and chronic leukemia. Current Concepts in the use of Doxorubicin Chemotherapy, Farmitalia, Ed. Stephen Jones, 87-94, 1982.
8. Durie BGM: Thyroid carcinoma. Current concepts in the use of Doxorubicin Chemotherapy, Farmitalia, Ed. Stephen Jones, 117-120, 1982.
9. Durie BGM: Chemotherapy of multiple myeloma Bailliere's Clinical Haematology, Vol. 4, No. 1:181-195, January 1991.
10. Durie BGM: Cellular and Molecular Genetic Features of Myeloma and Related Disorders. Hematology/Oncology Clinics of North America, Vol. 6, No. 2, April 1992.
11. Durie BGM: Myeloma and Other Paraproteinemias. Oxford Textbook of Medicine. Vol. 1 3rd Edition 1996.
12. Durie BGM: Epidemiology of Myeloma. Butterworth Press. 1997.
13. Durie BGM: Basic Biology and Treatment of Multiple Myeloma. Postgraduate Haematology. 1997.
14. Durie BGM: The role of imaging in multiple myeloma. Arnold Press, 155-163, 2004.
15. Durie BGM: Epidemiology of multiple myeloma and related disorders. Humana Press, 13-26, 2004.
16. Durie BGM: The role of imaging in multiple myeloma. Springer Publishing, 2008.

BOOKS

1. Russell DH, Durie BGM: Polyamines as Biochemical Markers of *Normal* and Malignant Growth. Progress in Cancer Research and Therapy, 8. Raven Press 1978.
2. Durie BGM: Multiple Myeloma: Concise Review (6 languages). International Myeloma Foundation Press 1993. New edition published 1998.
3. Durie BGM: Multiple Myeloma: Patient Handbook (6 languages). International Myeloma Foundation Press 1994.
4. Garton G and Durie BGM: Multiple Myeloma. First edition. Arnold Press. 1996.
5. Garton G, Durie BGM, Samson D. Multiple Myeloma and Related Disorders. 2nd Edition. Arnold Press. 2004.

VIDEOCASSETTES

1. Durie BGM, Redding KE: Bone marrow transplantation: One patient's experience. Video Cassette: Biomedical Communications, University of Arizona, 1983.
2. Durie BGM, Redding KE: Bone marrow transplantation: A donor's experience. Video Cassette: Biomedical Communications University of Arizona 1983.
3. Durie BGM, Redding KE: Bone marrow transplantation in acute leukemia. Video Cassette: Biomedical Communications, University of Arizona, 1983.

PUBLISHED ABSTRACTS

1. Durie BGM, Taswell HF: Mixed leukocyte culture in patients with myelomonocytic leukemia. Abstract No. 324, p. 14I, American Society of Hematology Fifteenth Annual Meeting, Hollywood, Florida, Dec. 3-6, 1972.
2. Salmon SE, Durie BGM: Kinetics of tumor cell growth in immunoproliferative disorders. Proceedings of the International Society of Hematology, September, 1974.
3. Jones SE, Lilien KL, O'Mara RE, Salmon SE, Durie BGM: Solid tumor scanning with indium-bleomycine. Proceedings of the American Association Cancer Research p90, 1974.
4. Lilian DL, Jones SE, O'Mara RE, Salmon SE, Durie BGM: A clinical evaluation of indium-bleomycin as a tumor imaging agent. (Abstract). Journal of Nuclear Medicine 15:512, 1974.
5. Salmon SE, Durie BGM: Critical role of temperature in high speed scintillation autoradiography (HSARG). CLIN RES. 23:406A, 1975.
6. Durie BGM, Hellman D, O'Mara R, Woolfenden J, Kartchner M, Salmon SE: Multimodality treatment for high risk thyroid carcinoma. ASCO 17:CI62, 1976.
7. Rosenblum MG, Durie BGM, Salmon SE, Chang S, Russell DH: A spermidine conjugate in body fluids of rats and humans. AACR 17:60, 1976.
8. Meezen E, Cole PW, Durie BGM, Salmon SE, Brendal K: Inhibition of Paminohippurate transport in isolated rabbit renal tubules Bence Jones protein, Fed Proc 35:2143, 1976.
9. Cole PW,, Salmon SE, Durie BGM: Quantitative radial immunodiffusion of free light chain immunoglobulins in myeloma patients. Fed Proc 35:377, 1976.

10. Durie BGM, Vaught L, Russell DH, Salmon SE: Dynamic Relationship of Cytokinetics to tumor burden and response to treatment in multiple myeloma. American Society of Hematology, 19th Annual Meeting, Boston, Mass., 128: 225, December 1976.
11. Durie BGM, Payne C, Kim HD, Fletcher J, Watts RB, Edholm J, Luthra M, Hanahan DJ: Detailed studies of unusual membrane abnormalities in a family with congenital dyserythropoietic anemia (CDA) type 1. American Society of Hematology, 19th Annual Meeting, Boston, Mass., 57:13, December 1976.
12. Durie BGM, Vaught L, Salmon SE: Prognostic significance of tritiated thymidine labeling index (LI) in multiple myeloma and acute myeloid leukemia. Proc. 68th Annual Meeting American Association for Cancer Research, Denver, Colorado, 80:320, May 1977.
13. Rosenblum MG. Durie BGM, Salmon SE, Russell DH: Pharmacokinetics of 14C-putrescine and 14C-spermidine in patients with cancer. Proc 68th Annual Meeting American Association for Cancer Research, Denver, Colorado, 80:320, May 1977.
14. Durie BGM, Salmon SE, Russell DH: Comparison clinical utility of plasma and urine polyamine determinations in cancer chemotherapy Proc 13th Annual Meeting American Society of Clinical Oncology, Denver, Colorado, 295:C-115, May 1977.
15. Eisenberg AC, Durie BGM, Huestis, DW: Prognostic factors and toxicity in patients receiving therapeutic and prophylactic granulocyte transfusions. American Society of Hematology, San Diego, California, Abstract 638, December 3-5, 1977.
16. Cole PW, Himmelstein KJ, Salmon SE, Durie BGM: Light chain immunoglobulin metabolic studies and the calculation of total tumor burden in Bence Jones myeloma patients. Fed Proc 37:1763, 1978.
17. Salmon SE, Soehanlen BJ, Durie BGM, Alberts DS, Meyskens FL, Chen H-SG, Moon TE: Clinical correlations of drug sensitivity in tumor stem cell assay. American Society of Clinical Oncology, May 1979.
18. Durie BGM, Young LA, Salmon SE: Clinical importance of kinetics in myeloma stem cell cultures. American Society of Clinical Oncology, May 1979.
19. Salmon S, Buick RN, Soehnlén BA, Trent JM Durie BGM, Alberts DS, Meyskens L: Human tumor cloning in vitro: Insights on biology kinetics and prediction of response to treatment. Abstract. Xth Meeting European Study group for the cell Proliferation.
20. Voakes J, Durie BGM, Levine A, Jett J, Levy h, Salmon S: Poly (ICLC) as an interferon inducer in refractory multiple myeloma. American Association of Cancer Research, 198.
21. Salmon S, Alberts D, Meyskens F, Durie BGM, Jones S, Soehnlén B, Young L: A new concept: In vitro phase II trial with the human tumor stem cell assay. American Society of Clinical Oncology 1980.

22. Ahmann F, Meyskens F, Jones S, Durie BGM, Alberts D, Salmon S: A broad phase II trial of AMSA with in vitro stem cell culture drug sensitivity American Association of Cancer Research, 1980.
23. Durie BGM, Salmon S: The kappa and lambda survival differences in multiple myeloma. Evidence for a biologic basis. American Society of Clinical Oncology, 1980.
24. Durie BGM: Recent advances in multiple myeloma. Swiss Society Hematology, Zurich, Switzerland, 1980.
25. Durie BGM: Cloning efficiency and monitoring of the chemotherapy of plasma cell myeloma. Ettore Majorana, Centre for Scientific Culture. International School of Medical Sciences. Advances in Lymphoproliferative Disorders. 15th course, 309-319, 1981.
26. Moon T, Salmon S, Alberts D, Chen G, Durie BGM, Meyskens F: Quantitative analysis of the human tumor stem cell assay (HTSCA) and the degree of association with clinical response. Proceedings, Seventeenth annual meeting of the American Society of Clinical Oncology (ASCO), 2/C- 61:348, 1981.
27. Herman TS, Durie BGM, Hutter J: Treatment of refractory acute myelogenous leukemia (AML) with vincristine, high dose methotrexate, 1 3-BIS-(2-Chlorethy)-1-Nitrosourea (BCNU), Cyclophosphide, and Methyl-Gloyoxal BIS-Guanylhydrazone (MGBG). Proceedings, Seventeenth annual meeting of the American Society of Clinical Oncology (ASCO), 22/c-559 476, 1981.
28. Durie BGM. Norris-Kloos L, Soehnlén B, Trnet JM: Cytogenetic analysis of clonogenic human acute myeloid leukemia (AML) and multiple myeloma (MM) cells. Proceedings, 72nd Annual Meeting of the American Association for Cancer Research (AACR), 22/600:151, 1981.
29. Hofmann V, Salmon SE, Durie BGM: Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine (TdR). Seventeenth Annual Meeting of the American Society of Clinical Oncology (ASCO), 22/C-794:536, 1981.
30. Salmon SE, Buick RN, Soehnlén B, Trent J, Durie BGM, Alberts D, Meyskens F: Human Tumor cloning in vitro: Insights an biology, kinetics, and prediction of response to treatment. Xth Meeting European Study Group for Cell Proliferation. Cell and Tissue Kinetics, 1981.
31. Hicks MJ, Layton JM, Ludwig C, Durie BGM, Powell M, Tabing T: Sex related differences in T cell subpopulations and the importance of sex-matched controls, Laboratory Investigation, 46:36A, 1982.
32. Durie BGM, Vaught L, Soehnlén B, Salmon SE: Sensitivity to interferons and bisantrene in refractory multiple myeloma: Comparison between thymidine suppression, myeloma stem cell culture, and clinical results. American Association for Cancer Research (AACR), April, 1982.

33. Dana BW, Durie BGM, Whie RF, Huestis DW, Paplanus S: Fungal infections in patients receiving granulocyte transfusions: Clinical course and risk factors, Western Section, AFCB, 1982.
34. Durie BGM, Ludwig CL: Smoldering myeloma: A analysis of patients developing overt disease. American Society of Hematology (ASH), in Blood, no. 50I, 60 (5):143a. 1982.
35. Bataille R, Durie BGM, Grenier J: Prognostic value of serum beta-2-microglobulin (S2-M) in multiple myeloma (MM): A prospective study of 107 patients. American Society of Hematology (ASH), Blood, no. 499, 60(5):143a, 1982.
36. Villar HV, Dunnington GL, Ranne RD, Durie BGM, Jones SE, Grogan TM: Hairy cell leukemia. The role of splenectomy. (Abst). Society of University Surgeons-45th Annual Meeting, February, 1984.
37. Durie BGM, Christiansen JA, Vela EE: Recent observations on enhanced cloning of multiple myeloma in vitro. Fourth conference on Human Tumor Cloning, Tucson Arizona. January, 1984
38. Garewal H, Durie BGM: High dose cytosine arabinoside, dacuomycin and G-thiaguanine in replaced acute myelogenous leukemia. Clinical Res. 32:24a, 1984.
39. Garewal H, Corrigan JJ, Durie BGM, et al: Effects of danazol on APTT, coagulant factor activity and bleeding in hemophilia. American Pediatric Society, 1984.
40. Berdeaux D, Glasser L, Serokman R, et al: Hypoplastic acute leukemia: Review of 70 cases. Blood 64 (5, suppl. 1): 145a, 1984.
41. Bataille R, Durie BGM, Grenier J: Prognostic factors and staging in multiple myeloma (MM): A re-appraisal, evaluating new parameters. Blood 64 (5, suppl. 1): 152a, 1984.
42. Durie BGM, Vela E, Vaum V, et al: Establishment of two new human myeloma cell lines from bilateral pleural effusions: Evidence for sequential clonal change. Blood 64 (5, suppl 1): 188a, 1984.
43. Villar HV, Peck ME, Hunter TB, et al: Gastrointestinal complications in leukemia patients. Society of Surgical Alimentary Tract, Vol. 31: 1143, 1984.
44. Durie BGM, Vela E, Payne C: Recent observations of amyloid production in myeloma colony culture. Ninth International Symposium of Amyloidosis, pg 90, November 9-12, 1984.
45. Rodriguez MA, Durie BGM, Meltzer PS: Evidence that a subset of human myelomas contain Epstein Barr Virus. J Clin Oncol, 4: 13(50), 1985.
46. Durie BGM, Dixon DO, Carter S, et al: Improved survival duration with combination chemotherapy induction for multiple myeloma. Am Soc Hematol, Abstract, Blood (Suppl), 66: 2201, (766), 1986.

47. Dalton WS, Durie BGM, Gerlach J, et al: Development and characterization of a new drug resistant human multiple myeloma cell line. Am Soc Hematol, Abstract, Blood (Suppl), 66: 220a, (766), 1986.
48. Clouse L, Braich T, Grimm M, et al: A phase I trial of oral cyclophosphamide (CTX) and subcutaneous recombinant alpha-2b-interferon (INF) in patients with malignant disease. Proc. Am Soc Clin Oncol, 5 (Abstr): 229 (892), 1986.
49. Dalton WS, Durie BGM, Grogan RM, et al: Cytogenetic and phenotypic analysis of a drug resistant human myeloma cell line. Proc AACR 27: 271 (1074), 1986.
50. Villar H, Dunnington G, Ranne R, et al: Hairy cell leukemia: the role of immunologic markers and splenectomy. (Abstract) Presented at the 106th annual meeting of the American Surgical Association, 1986.
51. Durie BGM, Baum VE, Vela EE, et al: Abnormalities of chromosome 6q and osteoclast activating factor (OAF; TNF-production in multiple myeloma. (abstract). Presented at American Society Hematology, December 1986.
52. Meltzer P, Shadle K., Durie BGM: Somatic mutation alters a critical region of the C-MYC gene in multiple myeloma (abstract). The American Society of Hematology, 29th annual meeting, Abst # 867, 1987.
53. Buzaid A, Durie BGM: Prednisone: and effective agent in refractory myeloma. Abst # 103, Western AFRC, 1987.
54. Meltzer PS, Shadle KM, Durie BGM: Characterization of a recurrent alterations of C-MYC in multiple myeloma. ASCO, Abst # 719, 1987.
55. Shadle KM, Meltzer PS, Durie BGM: Somatic mutation alters a critical region of the MYC gene in multiple myeloma (abstract). Clinical Research Vol. 36, 1988.
56. Buzaid AC, Durie BGM: Prednisone alone: an effective agent in refractory myeloma (abstract). Clinical Research Vol 36, 1988.
57. Durie BGM, Vela EE, Baum V. Cytogenetic abnormalities in multiple myeloma. Proceedings of Mechanisms of B cell Neoplasia, 1990.
58. Durie BGM, Vela EE, Frutiger Y. Macrophages as an important source of paracrine IL-6 in myeloma bone marrow. Proceedings of Mechanisms of a B cell neoplasia, 1990.
59. Durie BGM, Mason Dy, Giles F, Vela EE, Knight I, Wolff S, Foadi M, Samson D. Expression of the BCL-2 Oncogene Protein in Multiple Myeloma. Blood, Vol. 76, No. 10, Sup. 1, P 347a, 1990.
60. Giles FJ, Knight I, Vela EE, Jewell AP, Worman CP, Goldstone AH, Durie BGM. Serum interleukin 6 levels in patients with multiple myeloma: effects of cytotoxic chemotherapy, hemibody radiotherapy, BMT and alpha interferon. BSH, 1991 (Glasgow), submitted.

61. Buckner CD, Clift R, Durie BGM, Appelbaum FA, Hansen JA, Bianco J, Singer J, Storb R, Thomas ED. Allogeneic Marrow Transplantation for Multiple Myeloma Using Busulphan and Cyclophosphamide. *Blood*, Vol 76, No. 10, Supp 1, P527a,1990.
62. Durie BGM: The role of IL-6 in Myeloma. *Annals of Oncology*, Supp. 1 to Volume 3, March 1992, p 163.
63. Durie BGM: Role of Autologous and Allogenic Transplantations in Multiple Myeloma. *Proc. 1, BMTR Symp.* Feb 1994.
64. Durie BGM: Current Approaches to Myeloma Treatment. *Proc. Scripps Symp.* October 1994.
65. Durie BGM: The Demographics of Multiple Myeloma. *Symposium Royal College of Physicians. London Proceedings.* May 1994.
66. Durie BGM: Twin Transplants in Multiple Myeloma. *Proc IBMTR Symp.* February 1995.
67. Durie BGM: Mechanisms and Treatment of Bone Disease in Myeloma. *Proc. Europ. Onc. Symp.* Vienna, Austria. Sept 1996.
68. Durie BGM: What Causes Myeloma: review and update. *Proc. Cleveland Clinic Symp.* August 1996.
69. Durie BGM: Current Concepts of Myeloma Pathogenesis. *Proc. Myeloma Symp.* Sydney, Australia. April 1997
70. Durie BGM: Role of High-dose Therapy and Transplantation in Myeloma. *PROC Alta Bates Symp.* Inn at Spanish Bay. September 1997.
71. Durie BGM: Circulating DU-ALU Containing Sequence in Multiple Myeloma. *Blood.* Nov Abst 1070. 1997. (ASH)
72. Durie BGM: Clarithromycin as Treatment for Multiple Myeloma. *Blood Nov Abst* 2578. 1997. (ASH)
73. Durie BGM: FDG/PET Whole Body Scanning for Multiple Myeloma. *PROC INT SOC. Nuc Med.* Toronto, Canada. April 1998.
74. Durie BGM: Standard Dose Chemotherapy for Myeloma. *PROC. Royal College of Physicians Symp.* London. July 1998.
75. Durie BGM: Role of Viruses and Retroviruses in the Pathogenesis of Myeloma. *Swiss Haem. Symp.* Geneva, Switzerland. September 1998.
76. Durie BGM: New Paradigms in the Management of Myeloma. *Haem. Soc of Brazil. Am. Symp. Proceedings* Oct 1998.

77. Durie BGM: Current Approaches to Myeloma. PROC. Scripps Cancer Symp. San Diego. October 1998.
78. Durie BGM, Martin J: Stealth Virus and active myeloma: clinical correlations. BLOOD. 94:10 Suppl 1. November 15, 1999. (ASH)
79. Jacobson J, Hussein M, Barlogie B, Durie BGM, Crowley J: Beta 2 Microglobulin (B2M) and Albumin Define a New Staging System for Multiple Myeloma: The Southwest Oncology Group (SWOG) Experience. BLOOD. 98:11. November 16, 2001 Part 1. (ASH)
80. Durie BGM, Stepan D: Low Dose Thalidomide Alone and in Combination: Long Term Follow-Up. BLOOD. 98:11. November 16, 2001 Part 1. (ASH)
81. Durie BGM, Waxman A, D'Agnolo A: Prognostic Value of Whole Body FDG/PET Scanning In Multiple Myeloma. BLOOD. 96:11. November 16, 2002 Part 1. (ASH)
82. Durie BGM, Jacobson J, Barlogie B, Crowley J. Time to First Progression Is the Best Predictor of Survival Duration in SWOG Standard Dose Chemotherapy Studies. American Society of Hematology (ASH). December 2002.
83. Durie BGM, Mundy GR. Statin Use and the Likelihood of Bone Disease in Newly Diagnosed Myeloma: Abstract 5097. Blood, 100: 383b, 2002. (ASH)
84. Jagannath S, Durie BGM, Wolf J, et al. Bortozemib (VELCADE™, Formerly PS-341) as first-line therapy in patients with Multiple Myeloma: Abstract #1650. Blood, November Supplement, 2003. (ASH)
85. Jagannath S, Durie BGM, Wolf J, et al. First-line therapy with Bortozemib (VELCADE™, Formerly PS-341) in patients with Multiple Myeloma: Abstract #6551. J Clin Onc, 23: 568, June 2004. (ASCO)
86. Ludwig H, Durie BGM, Bolejack V, et al. Multiple myeloma (MM) in young patients (pts): Clinical features and outcome in 259 patients younger than 40 years in comparison to 8,296 pts aged 40 years: Abstract #3414. Blood, 106 (11), December 2005. (ASH)
87. Hussein MA, McCoy J, Durie B, et al. SWOG 0204: Phase 2 trial of thalidomide (T) + dexamethasone (D) induction followed by tandem autotransplant (TAT) and prednisone (P) + T maintenance for multiple myeloma (MM): Abstract #1169. Blood, 106 (11), December 2005. (ASH)
88. Dhodapkar MV, Zhan F, Durie B, et al. Gene expression profiling of bulk CD138+ plasma cells in preneoplastic gammopathy/ asymptomatic myeloma identifies distinct subsets of patients. Abstract #1218. Blood, 106 (11), December 2005. (ASH)

89. Johnson DC, Grindle J, Durie BGM, et al. Inherited genetic variation and the risk of developing venous thrombosis with thalidomide treatment in myeloma patients. Abstract #1624. Blood, 106 (11), December 2005. (ASH)
90. Zonder JA, Durie BGM, et al. High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis. Abstract #3455. Blood, 106 (11), December 2005. (ASH)
91. Van Ness BG, Durie BGM, et al. SNP genotypes show association with common toxicities during both VAD induction and high dose melphalan with autologous transplant support in intergroup trial S3921 for myeloma: from the Bank on a Cure. Abstract #3488. Blood, 106 (11), December 2005. (ASH)
92. Van Ness B, Crowley J, Durie BGM, et al. SNP genotypes as prognostic factors associated with staging in myeloma: the first combined SNP association analysis of SWOG, ECOG, and MRC clinical trials from the Bank on a Cure. Abstract #3489. Blood, 106 (11), December 2005. (ASH)
93. Van Ness B, Crowley J, Durie BGM, et al. Incidence, outcomes, and SNP genotypes show different ethnic association in patients with myeloma, assessed in SWOG and ECOG clinical trials S9321 and E9486: from the Bank on a Cure. Abstract #506. Blood, 106 (11), December 2005. (ASH)
94. Johnson DC, Grindle SM, Durie BGM, et al. Development of a panel of 3,500 SNP based functional genetic variants relevant to the etiology and outcome in multiple myeloma. Abstract #620. Blood, 106 (11), December 2005. (ASH)
95. Jagannath S, Durie BGM, et al. Bortezomib therapy alone and in combination with Dexamethasone for patients with previously untreated multiple myeloma. Abstract #783. Blood, 106 (11), December 2005. (ASH)
96. Durie BGM, et al. Circulating Nucleic Acids in multiple myeloma: presence of non-coding/ intergenic DNA reflects disease activity. Abstract #5095. Blood, 106 (11), December 2005. (ASH)
97. Spisek R, Chen L-C, Durie BGM, et al. Differential antigenic targets of anti-tumor immune response and selective immunity to stem cell associated group B SOX proteins in preneoplastic versus malignant gammopathy. Abstract #5116. Blood, 106 (11), December 2005. (ASH)
98. Van Ness B, Crowley J, Durie BGM, et al. SNP associations with event free survival in myeloma from two phase III clinical trials using the Bank on a Cure chip. Abstract #131. Blood, 108(11), December 2006. (ASH)
99. Jagannath S, Durie BGM, et al. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma. Abstract #796. Blood, 108(11), December 2006. (ASH)

100. Morgan GJ, Johnson DC, Durie BGM, et al. The genetic contribution to the aetiology of thalidomide associated VTE. Abstract #246. Blood, 108(11), December 2006. (ASH)
101. Durie BGM and Jones H. New bioaccumulations of toxins in resident coastal dolphins signal dangers of human myeloma. Abstract #5062. Blood, 108(11), December 2006. (ASH)
102. Durie BGM, et al. Deep vein thrombosis in myeloma: estimates of problem and recommendations for therapy based upon a survey of members of the International Myeloma Working Group. Abstract #3571. Blood, 108(11), December 2006. (ASH)
103. Bertolotti, P, Bilotti B, Durie BGM, et al. Nursing guidelines for enhanced patient care. Presented Abstract for XIth IMW 2007.
104. Zonder JA, Crowley J, Hussein MA, et al. Superiority of lenalidomide (Len) plus high dose dexamethasone (HD) compared to HD alone as treatment of newly-diagnosed multiple myeloma (NDMM): Results of the randomized, double-blinded, placebo-controlled SWOG trial S0232. Abstract #77. Blood, 110(11), November 2007 (ASH).
105. Jagannath S, Bensinger B, Vescio R, et al. A phase II study of bortezomib (VELCADE[®]), cyclophosphamide (Cytoxan[®]), thalidomide (Thalomid[®]) and dexamethasone as first-line therapy for multiple myeloma. Abstract #188. Blood, 110(11), November 2007 (ASH).
106. Durie BGM, Van Ness B, Ramos C, et al. Genetic polymorphisms identify the likelihood of bone disease in myeloma: Correlations with myeloma cell DKK1 expression and high risk gene signatures. Abstract # 816. Blood, 110(11), November 2007 (ASH).
107. Morgan GJ, Jenner MW, Walker BA, et al. An integrated pharmacogenomics strategy for the definition of thalidomide response signatures in presenting cases of multiple myeloma. Abstract #2493. Blood, 110(11), November 2007 (ASH).
108. Zonder JA, Crowley JJ, Bolejack V, et al. A randomized Southwest Oncology Group study comparing dexamethasone (D) to lenalidomide + dexamethasone (LD) as treatment of newly-diagnosed multiple myeloma (NDMM): Impact of cytogenetic abnormalities on efficacy of LD, and updated overall study results. Abstract #8521. J Clin Oncol. 26(15S), 2008 (ASCO).
109. Durie B. Treatment of haematological malignancies: Durable remissions and quality of life as primary goals. June 2008 (EHA).